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ABSTRACT 
Kaposi’s sarcoma herpesvirus (KSHV) is an oncogenic human virus and the 
causative agent of three human malignancies: Kaposi’s sarcoma (KS), Multicentric 
Castleman’s Disease (MCD), and primary effusion lymphoma (PEL). In tumors, 
KSHV establishes latent infection during which it produces no infectious particles. 
Latently infected cells can enter the lytic replication cycle, and upon provision of 
appropriate cellular signals, produce progeny virus. PEL, commonly described in 
patients with AIDS, represents a diffuse large-cell non-Hodgkin’s lymphoma, with 
median survival time less than six months after diagnosis. As tumor suppressor gene 
TP53 mutations occur rarely in PEL, the aim of this thesis was to investigate whether 
non-genotoxic activation of the p53 pathway can eradicate malignant PEL cells.  
This thesis demonstrates that Nutlin-3, a small-molecule inhibitor of the p53-
MDM2 interaction, efficiently restored p53 function in PEL cells, leading to cell cycle 
arrest and massive apoptosis. Furthermore, we found that KSHV infection activated 
DNA damage signaling, rendering the cells more sensitive to p53-dependent cell 
death. We also showed in vivo the therapeutic potential of p53 restoration that led to 
regression of subcutaneous and intraperitoneal PEL tumor xenografts without 
adversely affecting normal cells. Importantly, we demonstrated that in a small subset 
of intraperitoneal PEL tumors, spontaneous induction of viral reactivation dramatically 
impaired Nutlin-3-induced p53-mediated apoptosis. Accordingly, we found that 
elevated KSHV lytic transcripts correlated with PEL tumor burden in animals and that 
inhibition of viral reactivation in vitro restored cytotoxic activity of a small-molecule 
inhibitor of the p53-MDM2 interaction.  
Latency provides a unique opportunity for KSHV to escape host immune 
surveillance and to establish persistent infections. However, to maintain viral 
reservoirs and spread to other hosts, KSHV must be reactivated from latency and enter 
into the lytic growth phase. We showed that phosphorylation of nucleolar 
phosphoprotein nucleophosmin (NPM) by viral cyclin-CDK6 is critical for 
establishment and maintenance of the KSHV latency.  
In short, this study provides evidence that the switch between latent phase and 
lytic replication is a critical step that determines the outcome of viral infection and the 
pathogenesis of KSHV-induced malignancies. Our data may thus contribute to 
development of novel targeted therapies for intervention and treatment of KSHV-
associated cancers.  
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REVIEW OF THE LITERATURE 
 
1. Tumor suppressor protein p53 
1.1 Discovery of p53 
The SV40 DNA tumor virus became a popular research model for in vitro cell 
transformation studies in the 1970s. Several independent laboratories in 1979 reported 
the discovery of a 53-kDa protein interacting with the SV40 large T-antigen in 
transformed murine cells (Chang et al., 1979; Kress et al., 1979; Lane and Crawford, 
1979; Linzer and Levine, 1979; Linzer et al., 1979). This newly discovered protein 
was designated a cellular T-antigen and was regarded as an important target of SV40 
large T-antigen. Further studies confirmed its high levels in a variety of transformed 
mouse cells as well in biopsies of cancer-affected patients (DeLeo et al., 1979; Barque 
et al., 1983). Additional work by Mercer and coworkers (1982) enhanced interest in 
this protein, since it was found to delay the S-phase of the cell cycle. Interestingly, the 
TP53 gene was later cloned from neoplastic mouse and human cells and was found to 
possess oncogenic properties when expressed in rodent cells. In the late 1980s, 
however, it was discovered that researchers were investigating missense mutants 
instead of the wt gene. Starting from the early 1990s, TP53 was generally recognized 
as a tumor suppressor gene, called “Guardian of the genome,” that was mutated or lost 
in approximately half of all human cancer cases (Hollstein et al., 1991; Levine et al., 
1991; Lane, 1992). Not surprisingly, mice lacking TP53 are predisposed to 
spontaneous tumorigenesis (Donehower et al., 1992), and germ-line TP53 mutations 
arise in individuals with the cancer-prone Li-Fraumeni syndrome (Srivastava et al., 
1990; Malkin et al., 1992). With these data, the hunt for the accurate role of p53 as a 
tumor suppressor intensified, leading to an explosion of >50 000 scientific reports in 
the literature since the 1990s, all aimed at better understanding the function of p53 in 
tumorigenesis. 
 
1.2 p53 structure 
The TP53 gene is localized in the short arm of chromosome 17 (17q13) and encodes a 
tetrameric transcription factor of approximately 400 amino acid (aa) residues in length 
(393 aa in humans) (Friedman et al., 1993; Wang et al., 1994). p53 consists of five 
distinct domains: a transactivation domain, a proline-rich region, a core domain, an 
oligomerization domain, and a C-terminal basic domain. The core, also known as a 
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DNA-binding domain, is responsible for binding to the sequence-specific DNA 
elements located in close proximity to the p53 target gene promoters (Cho et al., 
1994). In contrast to other transcription factors, p53 possesses a second DNA-binding 
domain located on its C-terminus (residues 323 to 393) and creating stable complexes 
with DNA in a non-specific manner. These sites include mismatched DNA and 
double- or single-stranded DNA (Bakalkin et al., 1995; Lee et al., 1995). Interestingly, 
the same region of the C-terminal domain controls the efficiency of p53 to function as 
a transcription factor. Its post-translational modifications and interactions with other 
proteins are involved in modulating of the stability of p53-specific DNA complexes 
(Ko and Prives, 1996; Vogelstein et al., 2000). It is therefore possible that interactions 
between the core and the C-terminal domains of p53 may, upon its activation and 
stabilization, require allosteric reorganization of the p53 molecule (Hupp and Lane, 
1994). 
 
1.3 The p53 family 
Two structural homologs of p53, called p63 and p73, were discovered in 1997 
(Kaghad et al., 1997; Schmale and Bamberger, 1997; Trink et al., 1998; Yang et al., 
1998). Both, p63 and p73 display high levels of sequence similarity in the 
transactivation (TA), oligomerization, and highly conserved DNA-binding domain. 
This allows p63 and p73 to transactivate p53-responsive genes, and triggers cell cycle 
arrest and apoptosis. Due to their overall structure and sequence homology, p63, p73, 
and p53 form a family of transcription factors that evolved from a common 
predecessor (Yang et al., 2002a). Nevertheless, they are not completely redundant, and 
the primary role of each p53 family member - as determined by transgenic knockout 
(KO) mice - shows that each member plays its own unique role. Whereas the TP53 KO 
mice are viable and develop normally (Donehower et al., 1992), studies on p63 KO 
mice reveal developmental failures in skin and epithelial tissues and show restricted 
viability up to a few days after birth (Mills et al., 1999). The p73 KO mice are 
predisposed to inflammatory and neurological defects (Yang et al., 1999). 
 
Although p63 and p73 show an analogous domain structure, they are transcribed from 
two alternate promoters. This results either in the N-terminal transactivating forms 
TAp63 and TAp73 or the N-terminally truncated, transcriptionally impaired forms 
ΔNp63 and ΔNp73, which lack the TA domain and can exert dominant-negative 
effects on the TA forms (Stiewe, 2007). For instance, high expression of ΔNp63α can 
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promote survival of tumor cells by inactivating TAp73α (Rocco et al., 2006). 
Furthermore, a study by Bourdon and coworkers (2005) revealed an alternative 
promoter in the TP53 gene and identified multiple p53 splice variants. TAp63 and 
TAp73 activate a subset of p53 target genes implicated in cell cycle progression and 
apoptosis. They are also necessary for p53-dependent apoptosis in response to DNA 
damage and play a role in resistance to tumor formation (Tomasini et al., 2008a; 
Tomasini et al., 2008b). Interestingly, recent data indicate that p63 and p73 may 
suppress tumorigenesis by transcriptional regulation of genes involved in the DNA 
repair pathway (Lin et al., 2009). 
 
1.4 Regulation of p53  
The p53 tumor suppressor protein is regulated at numerous levels, and new studies 
have further broadened our knowledge of how this protein is controlled. A broad range 
of negative and positive regulators acting in feedback loops exert their functions at 
three different levels: protein stability, protein activity, and subcellular localization. As 
it is beyond the scope of this thesis to review all possible aspects of p53 regulation, it 
will therefore focus on regulation of p53 protein stability, with special emphasis on 
mouse double minute protein 2 (MDM2) function and the regulation of p53 by 
phosphorylation.  
 
1.4.1 Control of p53 stability by MDM2 
The ubiquitin-mediated proteasomal degradation pathway plays a major role in the 
regulation of p53 protein levels in normal cells (Michael and Oren, 2003; Brooks and 
Gu, 2006). MDM2 possesses ubiquitin E3-ligase activity with great specificity towards 
p53 (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997). First, MDM2 binds 
p53 at its DNA-binding domain so that p53 cannot function as a transcription factor. 
Later, MDM2 labels p53 for degradation, and finally, MDM2 is responsible for the 
export of p53 from the nucleus to the cytoplasm, abolishing its transcriptional activity 
(Kruse and Gu, 2009). The significance of the p53 negative regulation by MDM2 was 
demonstrated by series of elegant experiments with MDM2 KO mice in which early 
embryonic lethality due to MDM2 deficiency was abolished in mice concurrently 
deficient in p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995). Many human 
cancers overexpress MDM2, which seems adequate to inactivate p53 function without 
further need for p53 mutation (Momand et al., 2000). Equally, failure in MDM2 
expression causes massive in vivo apoptosis (de Rozieres et al., 2000). Therefore, 
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regulation of p53 by MDM2 is based on the negative feedback loop, in which p53 
induces the transcription of MDM2, whereas MDM2 promotes p53 turnover (Juven et 
al., 1993; Haupt et al., 1997; Kubbutat et al., 1997). 
 
Because MDM2 belongs to RING-finger ubiquitin ligases, it possess no intrinsic 
enzymatic activity (Fang et al., 2000; Honda and Yasuda, 2000). It acts in concert with 
the ubiquitin-conjugating enzymes (E2) UbcH5B and UbcH5C to relocate ubiquitin 
directly on p53 (Saville et al., 2004). Importantly, p53 oligomerization is fundamental 
for its ubiquitination and subsequent degradation by MDM2, since elimination of 
amino acids from the p53 C-terminus weakens its MDM2-dependent degradation 
(Kubbutat et al., 1998). Several lysines operate as potential ubiquitination sites. 
Replacement between residues 370 to 386 impairs ubiquitination of p53 by MDM2 
and impairs its responsiveness to MDM2-dependent degradation (Nakamura et al., 
2000; Rodriguez et al., 2000). In contrast, the proline region protects p53 against 
MDM2-dependent degradation, and deletion of residues 62 to 91 from this region of 
p53 results in hypersensitivity to MDM2 (Berger et al., 2001). Interestingly, the 
neighboring residues 92 to 112 are required for MDM2-dependent degradation of p53, 
which may suggest involvement of other proteins in the ubiquitination signaling (Gu et 
al., 2000).  
 
MDM2 causes mono- and poly-ubiquitination of p53, and these actions depend on 
MDM2 level. High levels of MDM2 induce p53 poly-ubiquitination, leading to 
degradation in the nucleus, whereas low levels trigger mono-ubiquitination with 
concomitant nuclear export of p53 (Xirodimas et al., 2001; Li et al., 2003).  
A prerequisite for poly-ubiquitination of p53 is the involvement of the transcriptional 
co-activator p300 (Grossman et al., 2003). Mutants of MDM2 that do not bind p300 
promote mono-ubiquitination of p53, but are unable to execute poly-ubiquitination and 
fail to target p53 for degradation (Zhu et al., 2001; Grossman et al., 2003).  
Ubiquitination of p53 takes place predominantly in the nucleus, despite some amount 
of p53 and MDM2 localized in the cytoplasm (Yu et al., 2000). Disruption of the 
nuclear localization signal (NLS) of p53 prevents it from entering the nucleus, and also 
blocks the MDM2-dependent ubiquitination. Following poly-ubiquitination, p53 may 
be destroyed either in the nucleus or in the cytoplasm (Xirodimas et al., 2001). 
Importantly, cytoplasmic degradation of p53 is tightly associated with transport of 
poly-ubiquitinated p53 that requires a C-terminal nuclear export sequence of p53 
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(Geyer et al., 2000). Previous studies suggested mono-ubiquitination and cytoplasmic 
re-localization of p53 as an alternative mechanism to block nuclear function of p53. 
However, recent data suggest its role in apoptosis and autophagy (Tasdemir et al., 
2008). Shortly after its relocalization to the cytoplasm, p53 may enter the mitochondria 
where it triggers apoptosis (Marchenko and Moll, 2007). It interacts with Bcl-xL and 
Bcl-2, anti-apoptotic proteins of the Bcl family, and supports oligomerization of pro-
apoptotic Bak and Bax. These events lead to formation of pores in mitochondria, to 
cytochrome c release, and to activation of other apoptotic factors (Mihara et al., 2003; 
Chipuk et al., 2004; Tomita et al., 2006). 
 
1.4.2 Role of ARF in p53 regulation 
A key regulator of the MDM2-dependent degradation of p53 is alternative reading 
frame (ARF), a product of the cyclin-dependent kinase (CDK) inhibitor 2A gene 
(CDKN2A) (Sherr, 2001). ARF is a protein with tumor suppressor activity, and its loss 
results in a phenotype that is similar to p53 deficiency (Kamijo et al., 1997). ARF 
binds to MDM2, represses its ubiquitin ligase activity, and as a consequence leads to 
p53 stabilization and the induction of apoptosis (Kamijo et al., 1998; Pomerantz et al., 
1998). More precisely, ARF has been shown to be a nucleolar protein which sequesters 
MDM2 into the nucleolus and stabilizes nucleoplasmic p53 (Weber et al., 1999). In 
addition, to its repressor function on MDM2, ARF controls and modifies activity of 
other E3 ubiquitin ligases. Accordingly, it is reported that ARF-BP1 ligase plays a role 
in the ARF p53-dependent activity (Chen et al., 2005a).   
 
1.4.3 MDM2-MDMX network in p53 regulation 
Regulation of p53 is also mediated through proteins that directly interact with and 
modulate the inhibitory effects of MDM2. One important regulator of MDM2 function 
is MDMX (HDMX), known also as MDM4. These proteins are structurally similar and 
interact with each other through the C-terminal RING domains. MDMX stabilizes both 
MDM2 and p53, and, in addition also promotes the E3-ligase activity of MDM2 
(Linares et al., 2003; Poyurovsky et al., 2007; Uldrijan et al., 2007). Interestingly, 
even though MDMX is a RING-domain protein, it has no E3-ligase activity for p53 
but rather inhibits p53 transcriptional activity (Marine et al., 2005). Research on the 
functional network between p53, MDM2, and MDMX has provided evidence that 
MDMX predominantly represses p53 function, but does not trigger p53 degradation 
(Marine et al., 2006; Wahl, 2006; Iwakuma and Lozano, 2007). It is possible that both 
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MDM2 and MDMX may repress transcription of p53 target genes by forming a protein 
complex with p53 on the promoters of specific p53-responsive genes. Importantly, 
acetylation counteracts down-regulation of p53 function by blocking the recruitment of 
both MDM2 and MDMX to p53-responsive promoters (Tang et al., 2008).  
 
Intriguingly, a study by Ringhausen and coworkers (2006) has shown that p53 may 
also be degraded in the MDM2-null cells. In addition, newly reported E3-ubiquitin 
ligases such as Arf-BP1, COP1, and Pirh2 have been confirmed to regulate p53 levels 
in vitro (Leng et al., 2003; Dornan et al., 2004; Chen et al., 2005a). These results 
strongly suggest some MDM2-independent mechanisms that may also be involved in 
the control of p53 stability.  
 
1.4.4 Regulation of p53 activity by phosphorylation 
The switch of p53 from an inactive to an active state can be modulated by a variety of 
post-translational modifications. Phosphorylation is by far the most studied 
modification associated with the activation of p53 in response to cellular stress. One 
site constitutively phosphorylated on p53 is Ser33. GSK-3β and the CDK-activating 
kinase (CAK) complex (Cdk7-Mat1-cyclinH) phosphorylate this site in unstressed 
cells. This phosphorylation affects the association of p53 with other proteins 
interacting with the N-terminus, such as MDM2 and the TAFs (Ko et al., 1997; 
Turenne and Price, 2001). In addition, p53 Thr55 is phosphorylated in quiescent cells 
by TAF1, and this phosphorylation enhances association of p53 with a protein 
promoting cytoplasmic translocation of p53, the nuclear export factor CRM1 (Gatti et 
al., 2000; Li et al., 2004a; Cai and Liu, 2008). Ser376 and Ser378 are also 
phosphorylated in proliferating cells by the CAK complex, but their physiological role 
is not fully understood (Lu et al., 1997). The majority of the phosphorylated p53 
appears in response to cellular stress, and one particular phosphorylation site depends 
on the inducer. Accordingly, Thr18 is primarily phosphorylated after ionizing 
irradiation (IR), whereas ultraviolet (UV) irradiation results in phosphorylation of 
Ser9, Ser33, and Ser37 (Saito et al., 2003). In addition, after IR, phosphorylation of 
p53 peaks at 2 to 4 hours, whereas upon UV irradiation, it occurs between 8 and 24 
hours. Several kinases involved in the DNA-damage response such as ATM, ATR, 
Chk1, and Chk2 have been determined to phosphorylate p53 (Siliciano et al., 1997; 
Shieh et al., 2000). Which one of these kinases will phosphorylate p53 depends on the 
cellular stress. IR activates phosphorylation of p53 by ATM and Chk2, whereas kinase 
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activity by ATR and Chk1 occurs upon UV irradiation or hypoxia (Bartek and Lukas, 
2003). Both ATM and ATR kinases phosphorylate p53 protein at Ser15 (Ser18 in 
mice) to increase its transactivation activity (Banin et al., 1998; Canman et al., 1998; 
Nakagawa et al., 1999; Tibbetts et al., 1999). Moreover, ATM has been reported to 
bind and phosphorylate MDM2 and therefore to promote p53 stabilization and 
accumulation in cells (Khosravi et al., 1999). Interestingly, ATM and ATR control p53 
also through other kinases. ATM activates Chk2 kinase, which phosphorylates p53 at 
Ser20. This modification is essential for p53 stabilization, as it modulates binding 
between p53 and MDM2 (Chehab et al., 1999). Phosphorylation of both Ser15 and 
Ser20 has been demonstrated as essential for the induction of p53-mediated apoptosis, 
which also requires p53 acetylation by p300 (Chao et al., 2003; Sluss et al., 2004). 
 
1.5 Functions of p53 
The p53 tumor suppressor protein responds to a variety of stresses, including DNA 
damage, hypoxia, cell cycle aberrations, oncogene activation, and virus infections. The 
exact molecular pathways activating p53 depend on type of stimuli and cell type. 
These determine the precise downstream effectors and cellular response such as growth 
arrest, apoptosis, or senescence (Fig. 1). The functional activation of the p53 pathway 
occurs either by transcriptional regulation of p53 target genes or by transcription-
independent mechanisms (Mirza et al., 2003; Harms et al., 2004). 
 
1.5.1 Role of p53 in cell cycle arrest 
Growth inhibition occurring in the late G1 phase is crucial for the protection of 
genome stability, as it prevents the replication of damaged DNA. The p53 target gene 
CDKN1A (p21CIP1) plays a key role in the p53-dependent G1 arrest (el-Deiry et al., 
1993; el-Deiry et al., 1994); p21CIP1 is a CDK inhibitor (CKI) and inhibits CDKs by 
binding to the cyclin-CDK complex, thus blocking S-phase entry (Harper et al., 1993). 
Interestingly, p53 can also act during the DNA synthesis, and this activity is mediated 
by alternative isoforms of the p53 protein (Rohaly et al., 2005) that participate in the 
induction of the 14-3-3σ and p21CIP1 proteins (Hermeking and Benzinger, 2006). The 
ability to inhibit the G2/M transition is essential to avoid segregation of damaged and 
partially replicated chromosomes. The block at this checkpoint occurs through 
inhibition of the Cyclin B/CDK1 complex (Peng et al., 1997), and several p53-
regulated target genes such as GADD45, BTG2, and MCG10 participate in this process 
(Rouault et al., 1996; Zhan et al., 1998; Wang et al., 1999; Zhu and Chen, 2000). In 
  REVIEW OF THE LITERATURE  
                - 9 - 
addition, p53 has been demonstrated to associate with centrosomes in mitotic cells 
(Ciciarello et al., 2001). Blockage of the assembly of the mitotic spindle by 
nocodazole leads to activation of p53 by ATM and in consequence to G1 arrest, with 
concomitant disruption of the p53 centrosomal localization(Ciciarello et al., 2001).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Simplified scheme of the regulatory network of the p53 pathway. In response to stress 
signals, p53 is activated through various only partly understood activation pathways. In conjunction 
with the coactivating acetyltransferases p300/CBP, p53 regulates the transcription of a variety of target 
genes, which determines cellular response. In a tightly controlled feedback loop, p53 also induces 
expression of its negative regulators, such as the E3 ubiquitin ligase MDM2, which binds to p53 and 
promotes its ubiquitination, followed by nuclear export and proteasomal degradation. This process, 
together with the action of other E3 ubiquitin ligases, keeps cellular p53 levels constitutively low. 
Moreover, MDM2 competes with p300/CBP in binding to the p53 N-terminus. Regulation of p53 
activity also involves the MDM2 homolog MDM4, which acts in both distinct and synergistic ways. The 
complex p53 activation pathways either directly or indirectly disrupt this negative feedback loop 
(modified from Joerger and Fehrst, 2008).  
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1.5.2 Role of p53 in apoptosis 
Activation of p53 can execute apoptosis through the transcriptional activation of pro-
apoptotic target genes (Haupt et al., 2003). These targets are members of intrinsic and 
extrinsic apoptotic pathways. The intrinsic p53 apoptotic pathway involves induction 
of the pro-apoptotic Bcl-2 family members Bax and the BH3-only proteins Bid, 
PUMA, and Noxa (Oda et al., 2000; Nakano and Vousden, 2001; Sax et al., 2002). 
They act as activators stimulating Bax/Bak oligomerization and induce apoptosis 
through dislocation of the anti-apoptotic proteins from the Bax-Bak complex (Vaseva 
and Moll, 2009). Importantly, the BH3 domain plays a key role in the pro-apoptotic 
activity of these proteins (Cory and Adams, 2002).  
 
The first evidence of a direct role for p53 in mitochondrial apoptosis came from 
Marchenko and coworkers (2000), indicating that upon p53-dependent apoptosis, a 
small percentage of stabilized wt p53 promptly translocates to the outer membrane of 
the mitochondria. This translocation of p53 precedes modifications of mitochondrial 
membrane potential, cytochrome c release, and caspase activation (Marchenko et al., 
2000). After entering the mitochondria, p53 is promptly de-ubiquitinated by the 
HAUSP protein, which switches it to an active form (Li et al., 2002). Moreover, 
binding of p53 to Bcl-2 and Bcl-xL is regulated by the p53 DNA-binding domain 
(Petros et al., 2004). Interaction of p53 with the anti-apoptotic protein Bcl-xL releases 
the pro-apoptotic proteins Bax and Bid previously sequestered by Bcl-xL, enhancing 
their pro-apoptotic activity (Chipuk et al., 2004; Chipuk and Green, 2006). Upon its 
activation by the cytoplasmic p53, the Bax protein changes its conformation, which 
assists in its translocation from the cytosol into mitochondria (Chipuk et al., 2004; 
Schuler and Green, 2005). p53 binds to Bak in mitochondria and promotes its 
oligomerization and activation (Mihara et al., 2003; Erster et al., 2004; Schuler and 
Green, 2005). Moreover, p53 negatively regulates the anti-apoptotic protein called 
apoptosis repressor with caspase recruitment domain (ARC). Transcriptional 
repression of ARC by p53 leads to activation of the pro-apoptotic factors PUMA and 
Bad, and to initiation of the p53 apoptotic program (Li et al., 2008a). Interestingly, a 
recent study has shown that p53 promotes release of cytochrome c by inducing the 
expression of the OKL38 tumor suppressor gene. Loss of OKL38 is reported to drive 
tumorigenesis, whereas its overproduction triggers apoptosis in several carcinoma cell 
lines in vitro (Yao et al., 2008).  
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The extrinsic apoptotic response is initiated outside the cell and involves p53 to induce 
the expression of the death receptor Fas (CD95) and KILLER/DR5 (TRAIL receptor 
2) (Haupt et al., 2003). In addition, p53 activates expression of the TNFSF10 (TRAIL) 
death ligand, and the Fas ligand, TNFSF6 (FasL) (Maecker et al., 2000; Kuribayashi et 
al., 2008). Several lines of evidence indicate that p53 is also able to transactivate many 
other factors/genes of the apoptotic machinery, including apaf-1, caspase 8, and 
caspase 6 (Haupt et al., 2003), the apoptosis-enhancing nuclease implicated in DNA 
fragmentation (Kawase et al., 2008), and PIG3, a gene involved in redox metabolism 
(Polyak et al., 1997).  
 
1.6 Restoration of p53 function 
TP53 is the most frequently inactivated tumor suppressor gene in human malignancies, 
and its inactivation is advantageous for tumor survival. In about half of all human 
cancers, p53 is inactivated directly by mutations or deletions, whereas in the remaining 
half, p53 activity is suppressed due to malfunctions in the downstream pathways 
(Vogelstein et al., 2000). Any appropriate strategy for pharmacological restoration of 
p53 function will therefore critically depend on p53 mutation status. Several 
approaches have been undertaken to restore p53 function in tumors, and these 
strategies can be classified into four groups: (a) design of inhibitors for negative 
regulators of p53 in tumors with wt p53 status (Vassilev et al., 2004; Vassilev, 2005; 
Vassilev, 2007), (b) development of small molecules stabilizing and activating wt p53 
(Issaeva et al., 2004), (c) restoration of mutant p53 function with the ability to reverse 
the mutant p53 phenotype (Foster et al., 1999; Bykov et al., 2002a; Bykov et al., 
2002b; Bykov et al., 2005), and (d) tumor therapy based on expression of exogenous 
p53, for instance through adenoviral gene transfer (Cai et al., 1993; Rosenfeld et al., 
1995; Roth, 2006). Importantly, recent studies with transgenic mice, where p53 
expression is reversibly switched on/off, have independently demonstrated that 
restoration of p53 function leads to apoptosis and tumor regression in vivo. These 
studies indicate that restoration of the p53 pathway is a promising therapeutic modality 
against cancer (Martins et al., 2006; Ventura et al., 2007).  
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Figure 2. The negative p53-MDM2 regulatory feedback loop. Under physiological conditions, wt 
p53 has a very short half-life because of the autoregulatory negative feedback loop mediated by MDM2. 
First, wt p53 activates the transcription of the MDM2 gene; subsequently the MDM2 protein, upon 
interaction with the p53 transactivation domain, impairs p53 transcriptional activity. Moreover, MDM2, 
through its E3 ubiquitin ligase activity, promotes proteasome-dependent p53 degradation and modulates 
nuclear export of p53. Small-molecule inhibitor (red), which can bind specifically to the p53-binding 
pocket on the surface of MDM2, disrupts the p53-MDM2 interaction and releases p53 from MDM2 
control. Thus, by liberating p53 from MDM2 one might stabilize the tumor suppressor and activate the 
p53 pathway, leading to growth arrest and apoptosis. p53 continues to activate the MDM2 promoter, and 
the level of MDM2 will rise, but it will be unable to bind to p53 because of the small-molecule 
antagonists that keep the p53 pocket occupied. 
 
 
1.6.1 MDM2 antagonists 
Cellular levels of p53 are strictly regulated through the E3 ubiquitin ligase MDM2 that 
sequesters p53 for proteasomal degradation via ubiquitination (Fig. 2, see also 1.4.1). 
In many human cancers, MDM2 is exceedingly over-expressed (Momand et al., 1998), 
which efficiently abolishes p53 function regardless of p53 status. Therefore, MDM2 
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antagonists may present attractive targets of anti-cancer therapeutics for tumors with 
wt p53. In 2004, Vassiliev and coworkers (2004) identified a group of cis-imidazoline 
analogs termed Nutlins by screening a library of synthetic small-molecule compounds. 
These molecules disrupt the p53-MDM2 interaction through competition with p53 for 
MDM2. At cellular level, the consequences may result in cell cycle arrest in G1 and G2 
phases or apoptosis, or both (Fig. 2). Nutlins interact with and bind to the highly 
hydrophobic p53-binding pocket in the N-terminal domain of MDM2, thus mimicking 
the binding mode of a short peptide derived from the N-terminus of p53. The 
interaction between p53 and MDM2 involves three major hydrophobic residues (Phe-
19, Trp-23, and Leu-26) located in an amphipathic α -helix of p53 and in a deep 
hydrophobic p53-binding pocket in MDM2 (Kussie et al., 1996; Schon et al., 2002). 
Structural analysis reveals that in the MDM2-Nutlin complex an ethylether site of 
Nutlin resides in the Phe-19 binding pocket, whereas the bromophenyl groups are 
positioned in the Trp-23 and Leu-26 binding sites. The central imidazoline moiety 
operates as a scaffold for these groups (Vassilev et al., 2004). Nutlins were soon 
proven to be highly potent and specific inhibitors of the p53-MDM2 interaction in a 
variety of cancer cell lines expressing wt p53, but they failed to restore p53 in cell 
lines expressing mutant p53 (Vassilev, 2004; Tovar et al., 2006).  
 
In addition to Nutlins, several other potent small molecule inhibitors disrupt the p53-
MDM2 interactions. Benzodiazepinedione-based MDM2 antagonists were found 
through a series of screens with benzodiazepinediones and their derivatives 
(Grasberger et al., 2005; Parks et al., 2005). These inhibitors were further confirmed to 
stabilize p53 and trigger apoptosis in p53 wt hepatocellular carcinoma cells (Koblish et 
al., 2006).  High throughput screening of a large chemical library led to the discovery 
of non-peptidic MDM2 inhibitors based on a spiro-oxindole core (Ding et al., 2005; 
Ding et al., 2006). These inhibit growth of cancer cell lines with wt p53, and show 
approximately 50-fold weaker activity in cancer cell lines expressing mutant p53, 
further confirming the critical role of p53 status in cellular activity of the inhibitors. 
Interesting MDM2 inhibitors are α-helix mimetics of p53 (Kussie et al., 1996), non-
peptidic synthetic molecules based on the terphenyl scaffold. These compounds 
activate p53-dependent transcription and lead to strong cell cycle arrest in cells 
expressing wt p53 (Chen et al., 2005b; Yin et al., 2005). Alternative approaches to 
antagonize MDM2 in tumors include down-regulation of MDM2 expression with anti-
sense oligonucleotides as well as development of small-molecule chemicals that 
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exclusively target the E3 ubiquitin ligase activity of MDM2 (Chen et al., 1998; Tortora 
et al., 2000; Prasad et al., 2002; Zhang et al., 2004b; Zhang et al., 2005b). Moreover, 
approaches targeting p53-mediated protein-protein interactions are also plausible for 
other negative regulators of p53 such as MDMX (Michael and Oren, 2003). Although 
MDM2 and MDMX show structural similarities, Nutlin-3 does not inhibit MDMX (Hu 
et al., 2006; Wade et al., 2006). This may complicate the outcome of p53 restoration 
by MDM2 antagonists, especially in MDMX-overexpressing cancers (Toledo and 
Wahl, 2007). Collective inhibition of MDM2 and MDMX may therefore provide more 
effective anti-tumor activity for this kind of cancer (Toledo and Wahl, 2006; Hu et al., 
2007).  
 
1.6.2 Nutlin-3 as an innovative therapeutic tool in hematological malignancies 
Several hematological malignancies have retained wt p53, making them potential 
targets for MDM2 inhibitor-based therapy. Nutlin-3 effectively triggers apoptosis in 
acute myeloid leukemia (AML) and in B-chronic lymphocytic leukemia (B-CLL), as 
well as in multiple myeloma and mantle cell lymphoma (Kojima et al., 2005; Stuhmer 
et al., 2005; Coll-Mulet et al., 2006; Kojima et al., 2006; Secchiero et al., 2006; Tabe 
et al., 2009). Moreover, Nutlin-3 synergizes with doxorubicin and cytosine arabinoside 
in apoptosis of myeloblasts in AML and with doxorubicin, chlorambucil, and 
fludarabine in cell death of leukemic cells in B-CLL primary tumors (Kojima et al., 
2005; Coll-Mulet et al., 2006; Kojima et al., 2006; Secchiero et al., 2006). Of note, 
treatments with Nutlin-3 alone or in combination with genotoxic agents are selective 
for cancer cells, as demonstrated by their low toxicity to peripheral blood mononuclear 
cells or bone marrow-derived hematopoietic progenitors and to bone marrow stromal 
epithelium cells (Stuhmer et al., 2005; Secchiero et al., 2006). Brummelkamp and 
coworkers (2006) identified the DNA damage protein p53-binding protein 1 (53BP1) 
as an essential mediator of Nutlin-3-induced cytotoxic effect. While Nutlin-3 is not 
itself genotoxic (Thompson et al., 2004), studies with these compounds have 
strengthened the concept that activated DNA damage signaling occurs in cancer cells 
(Bartkova et al., 2005; Gorgoulis et al., 2005), and contributes to the cytotoxic activity 
of Nutlin-3. ATM protein kinase is a major regulator of p53 activity and a central 
mediator of cellular responses to DNA double-strand breaks (Jackson and Bartek, 
2009). Interestingly, whereas low levels of ATM rendered fludarabine treatment 
ineffective, ATM did not influence Nutlin-3 activity. These data suggest that MDM2 
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inhibitors may sustain their activity in tumors with no upstream signals activating p53 
(Kojima et al., 2006).  
 
An important factor contributing to chemoresistance in hematological malignancies is 
the X-linked inhibitor of apoptosis (XIAP) (Deveraux and Reed, 1999). Restoration of 
the p53 pathway synchronized with inhibition of XIAP greatly enhances activation of 
p53-dependent apoptosis both in AML cells and in chemoresistant primary blasts 
isolated from AML patients (Carter et al., 2010). Interestingly, an alternative 
therapeutic approach to the induction of apoptosis is to promote terminal growth arrest 
and maturation of AML blasts (Gorin et al., 2000). Intriguingly, Nutlin-3 promotes 
maturation not only in wt p53 myelocytic/monocytic lineages but also in the p53-/- 
leukemic cells (Secchiero et al., 2007). These results suggest a new role for Nutlin-3 as 
an anti-neoplastic agent for certain types of AML.  
 
Another interesting recent observation regarding chronic myeloid leukemia and 
Philadelphia chromosome-positive acute lymphoblastic leukemia is that Nutlin-3 
greatly enhances apoptosis induced by imatinib (a specific inhibitor of the BCR/ABL 
tyrosine kinase) by activation of Bax and caspase-3. These are normally inhibited in 
leukemias by over-expression of Bcl-xL (Kurosu et al., 2010). Furthermore, Nutlin-3 
also demonstrates autonomous biological activities distinct from cell death such as 
inhibition of vascular endothelial growth factor (LaRusch et al., 2007) and stromal-
derived factor-1/CXCL12 (Moskovits et al., 2006). The therapeutic potential of 
Nutlin-3 may therefore involve two different, but possibly not mutually exclusive, 
mechanisms of action. One mechanism is based on a cytotoxic effect towards 
malignant cells and the second, an indirect effect, against tumor stromal and vascular 
cells.  
 
2. Nucleophosmin (NPM), a multifunctional phosphoprotein 
NPM, also termed B23, NO38, or numatrin was originally identified as an abundant 
nucleolar phosphoprotein located in granular regions of the nucleolus (Feuerstein and 
Mond, 1987; Schmidt-Zachmann et al., 1987). It rapidly shuttles between the nucleus 
and cytoplasm and plays multiple roles in cell growth and proliferation (Borer et al., 
1989; Szebeni et al., 1995). NPM function has been linked to ribosome biogenesis 
(Prestayko et al., 1974; Spector et al., 1984; Yung et al., 1985), the synthesis and 
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processing of ribosomal RNA (rRNA) (Dumbar et al., 1989; Herrera et al., 1995; 
Savkur and Olson, 1998), and transport of rRNA and ribosomal proteins (Dutta et al., 
2001; Huang et al., 2005). Elevated NPM levels are evident in proliferating cells as 
well as in cancer cells, probably due to an increased requirement for ribosomal 
synthesis. Fluctuations in NPM abundance and shuttling properties modify cellular 
status with respect to proliferation, differentiation, and apoptosis (Grisendi et al., 
2006).   
 
2.1 NPM in centrosome duplication 
NPM undergoes a variety of post-translational modifications such as phosphorylation, 
sumoylation, acetylation, ubiquitination, and poly(ADP-ribosyl)ation all of which 
direct its cellular functions (Okuwaki, 2008). NPM also plays an important role in cell 
cycle regulation.  In interphase, the majority of NPM protein localizes to the nucleolus, 
whereas in mitosis it distributes itself throughout the nucleoplasm and associates with 
condensed chromosomes (Ochs et al., 1983). NPM is attached to single, unreplicated 
centrosomes in late G1 (Fig. 3), and undergoes phosphorylation at Thr199 by cyclin E-
CDK2 (Fig. 3), which causes NPM dissociation from the centrosome and its 
subsequent duplication (Okuda et al., 2000; Tokuyama et al., 2001; Okuda, 2002; 
Tarapore et al., 2002). A closer look at the centrosomal association with NPM reveals 
that NPM dissociates from centrosomes prior to the initiation of centrosome 
duplication (Fig. 3), implying a role for NPM in the pairing of centrioles (Shinmura et 
al., 2005). Meraldi and coworkers (1999) have shown that cyclin A-CDK2 may also 
play an important role in centrosome duplication. Whereas cyclin E-CDK2 kinase 
activity is low during the S phase, due to the instability of cyclin E protein (Dulic et 
al., 1992; Koff et al., 1992), the amount of cyclin A increases during the S phase and 
remains elevated throughout the G2 phase (Pines and Hunter, 1990; Marraccino et al., 
1992; Pagano et al., 1992). Importantly, NPM is also phosphorylated on Thr199 by 
cyclin A-CDK2 in vitro (Tokuyama et al., 2001), making it possible that the 
continuous activity of cyclin A-CDK2 may be responsible for preventing NPM from 
re-associating with centrosomes during the S and G2 phases. NPM re-associates with 
the centrosomes only in mitosis (Zatsepina et al., 1999; Okuda et al., 2000). Cha and 
coworkers (2004) report that the cyclin B-CDK1 complex, as a key controller of the M 
phase, phosphorylates the Thr234 and Thr237 sites of NPM and allows NPM to target 
the centrosome during mitosis.  
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Figure 3. Schematic model of NPM involvement in the control of centrosome duplication and 
mitosis. In early G1, centrosome-bound NPM dissociates from centrosomes after phosphorylation on 
Thr199 by cyclin E-CDK2. This phosphorylation leads to centriole separation and the initiation of 
centrosome replication. During centrosome duplication and maturation (S and G2 phases), cytoplasmic 
NPM is prevented from re-associating with centrosomes, an event that is probably mediated by the 
phosphorylation activity of cyclin A-CDK2. During mitosis, the re-association of NPM with the 
centrosome at the mitotic spindle depends on the phosphorylation activity of polo-like kinase 1 (PLK1) 
and never in mitosis gene A-related kinase 2 (NEK2A) mitotic kinases, the functions of which have 
been involved in the control of correct spindle formation and chromosome segregation (Adapted and 
modified from Grisendi et al., 2006). 
 
Of interest, phosphorylation of NPM on Ser4 by PLK1 may play a role in centrosome 
homeostasis and in cytokinesis (Zhang et al., 2004a). Furthermore, nuclear export of 
NPM by the Ran–Crm1 complex may also been involved in the NPM-driven induction 
of centrosome duplication. When NPM nuclear export signal mutants are over-
expressed or mouse skin fibroblasts are treated with leptomycin B, an inhibitor of 
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Crm1-mediated nuclear export, this effectively hampers NPM export. This then results 
in NPM accumulation in the nucleus, with subsequent dissociation from the 
centrosome (Shinmura et al., 2005; Wang et al., 2005b). In this regard, NPM acts as a 
suppressor of centrosome duplication. Indeed, NPM inactivation results in unrestricted 
centrosome duplication and aneuploidy (Grisendi et al., 2005), suggesting that NPM is 
essential for embryonic development and for the maintenance of genomic integrity. 
Furthermore, aberrant numbers of centrosomes have appeared upon dysregulation of 
cyclin E-dependent kinase activity and excessive phosphorylation of NPM (Saavedra 
et al., 2003; Zhang et al., 2004a). NPM may therefore serve as a tumor suppressor, 
since abrogation of its function results in tumorigenic phenotypes (Lim and Wang, 
2006). In contrast, NPM also controls cell proliferation and upon over-expression may 
show oncogenic potential. Importantly, one clinical study has shown a correlation 
between level of NPM and progression from early to advanced grades of ovarian 
cancer and of oral squamous cell carcinoma (OSCC) (Zhang, 2004; Shandilya et al., 
2009), implying that NPM functions as a positive regulator of cell proliferation during 
tumorigenesis (Lim and Wang, 2006).  
 
2.2 NPM involvement in transcriptional regulation 
NPM is a histone chaperone identified in Xenopus egg extracts as a factor that binds 
histones and loads them onto DNA (Laskey et al., 1978; Laskey and Earnshaw, 1980). 
NPM possesses chaperone activity for both nucleic acids and proteins, with its N-
terminal core domain being responsible for this activity (Szebeni and Olson, 1999; 
Hingorani et al., 2000; Okuwaki et al., 2001b). NPM can bind to histones H3, H4, and 
H2B, and assemble nucleosomes in vitro, like other members of the nucleoplasmin 
family (Okuwaki et al., 2001b; Namboodiri et al., 2004). Molecular chaperones 
including NPM are supposed to function by a dual mechanism either by aiming 
directly at chromatin remodeling through histone modifications or by modulating 
transcription through interaction with transcriptional regulatory partners. Murano and 
coworkers (2008) demonstrated that NPM associates with the rRNA gene chromatin, 
with the level of rRNA gene transcription proportional to the amount of NPM. Further 
experiments reveal that NPM inhibits histone-modifying enzymes such as GCN5 and 
therefore blocks GCN5-dependent acetylation of free and nucleosomal histones (Zou 
et al., 2008). Interestingly, NPM is also recruited to join the promoters of certain 
retinoic acid-responsive genes such as p120, heat-shock protein 60 gene (Hsp60), or b-
Myb, and NPM acts as a negative co-regulator of retinoic acid signaling (Liu et al., 
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2007a). Furthermore, NPM binds to c-Myc and is recruited to c-Myc target gene 
promoters such as eIF4E and tert, thereby controlling c-Myc transcriptional activity 
(Li et al., 2008b). As a co-regulator for the transforming activity of c-Myc, NPM 
enhances c-Myc-driven cell proliferation and transformation. 
 
Importantly, NPM protein undergoes other post-translational modifications in addition 
to phosphorylation. NPM is acetylated by the histone acetyltransferase p300 and is the 
only known chaperone to become acetylated with a functional consequence. 
Swaminathan and coworkers (2005) reported that NPM acetylation enhances its 
histone chaperone activity, and modulates in vitro transcription from chromatin 
templates by RNA Pol II in the presence of p300. In addition, acetylation of NPM 
results in an increase in p53-responsive synthetic reporter gene transcription. 
Importantly, acetylated NPM has a higher affinity for acetylated histones, which may 
facilitate histone exchange at the active gene promoters and in chromatin remodeling. 
Furthermore, high levels of acetylated NPM occur in OSCC isolated from patients 
(Shandilya et al., 2009). NPM has been shown to occupy the TNF-α promoter in 
conjunction with active RNAP II and p300 and to enhance gene expression. 
Intriguingly, acetylation of NPM is markedly higher in later stages of OSCC, 
suggesting that NPM acetylation status contributes during carcinogenesis to its 
oncogenic potential (Shandilya et al., 2009).  
 
Interestingly, one level of cell proliferation control at which NPM is involved 
comprises interactions with a number of transcription factors such us ARF, IRF-1, 
YY1, and NF-κB (Inouye and Seto, 1994; Kondo et al., 1997; Dhar et al., 2004; Chan 
et al., 2005; Korgaonkar et al., 2005). NPM can form a complex with YY1 and reverse 
the YY1 transcription repression function (Inouye and Seto, 1994). Later, NPM was 
found to play a pivotal role in the regulation of proliferating cellular nuclear antigen 
(PCNA) promoter through YY1 (Weng and Yung, 2005). In addition, NPM also 
controls the transcriptional activity of IRF-1 and p53 (Kondo et al., 1997; Colombo et 
al., 2002).  Interestingly, Dhar and coworkers (2004) demonstrated one role of NPM as 
an NF-κB co-activator in controlling the expression of the human superoxide 
dismutase 2 (SOD2) gene. Consistent with this role, an increase in NPM results in 
amplification of SOD2 transcription in a dose-dependent manner. Moreover, NPM is 
identified as a novel transcriptional regulator of E2F1 promoter by modulating the 
association of NF-κB, E2F1, and pRB, essential to activate this promoter (Lin et al., 
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2006). Recently, Leotoing and coworkers (2008) suggested that NPM may alter the 
activity of androgen receptor by regulating its binding to the androgen response 
element. In this regard, NPM may be involved in tumor progression through the 
androgen receptor signaling pathway.  
 
2.3 Biological role of NPM in tumorigenesis  
The exact role of NPM in cancer is multifaceted, as it seems to suppress the early 
stages of tumor formation but promote the growth of established cancer cells (Kondo 
et al., 1997; Colombo et al., 2002; Bertwistle et al., 2004; Kurki et al., 2004; 
Korgaonkar et al., 2005). The ability of NPM to suppress tumorigenesis at early stages 
may be related to its function in maintaining the DNA integrity and stability of the 
genome (Colombo et al., 2005; Grisendi et al., 2005). Loss of NPM leads to 
constitutive activation of the DNA damage response, because NPM-null mouse 
embryo fibroblasts (MEFs) show elevated levels of γ-H2AX, an indicator of DNA 
double-strand breaks (Colombo et al., 2002). This is in line with other findings that 
link NPM with the DNA repair process after UV radiation by up-regulating PCNA or 
GADD45, essential components of the DNA repair machinery (Wu et al., 2002; Gao et 
al., 2005). Upon UV exposure, NPM is up-regulated and directly binds to p53, and 
affects its transcriptional activity and checkpoint control (Wang et al., 1999; Colombo 
et al., 2002; Yang et al., 2002b; Maiguel et al., 2004). In regard to genome integrity, 
NPM therefore acts as a tumor suppressor by preventing DNA damage. 
 
NPM over-expression has been shown in many human cancers such as colon (Nozawa 
et al., 1996), ovarian (Shields et al., 1997), prostate (Subong et al., 1999), and gastric 
(Tanaka et al., 1992) cancers. In addition to interacting with p53, NPM binds to 
MDM2 (Kurki et al., 2004) and ARF (Itahana et al., 2003; Bertwistle et al., 2004; 
Brady et al., 2004) and regulates cell growth through the activities of these proteins. 
NPM interacts with the tumor suppressor ARF, a positive regulator of p53 (Bertwistle 
et al., 2004; Korgaonkar et al., 2005). ARF prevents the degradation of p53 by 
interacting with MDM2 to inhibit MDM2-mediated ubiquitination of p53. This leads 
to increased expression of p53 target genes responsible for cell cycle arrest or 
apoptosis (Gjerset and Bandyopadhyay, 2006). Because both NPM and MDM2 are 
able to bind to the N-terminus of ARF, NPM thus competes with MDM2 for binding 
to ARF. In consequence, NPM sequesters ARF to the nucleolus and inhibits its 
function (Korgaonkar et al., 2005). Interestingly, NPM acts as a nuclear PI(3,4,5)P3 
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receptor and binds to active CAD/DFF40 to inhibit apoptotic DNA fragmentation 
(Ahn et al., 2005). Moreover, several studies have shown NPM to be a co-activator for 
the transcription of survival genes such as Bcl-2, known as an oncogene from follicular 
lymphoma of B-cell origin (Bakhshi et al., 1985; Tsujimoto and Croce, 1986). NPM 
blocks mitochondrial p53 and prevents p53-mediated apoptosis (Dhar and St Clair, 
2009). NPM has also been shown to bind tumor suppressor IRF-1, a transcriptional 
activator in the interferon (IFN) system (Harada et al., 1989; Harada et al., 1993). 
NPM interaction with IRF-1-response elements leads to inactivation of IRF-1 
transcriptional activity and manifestation of oncogenic properties (Kondo et al., 1997; 
Hsu and Yung, 1998).  
 
Previous studies have shown NPM to be a direct transcriptional target of the c-Myc 
proto-oncogene, and expression of c-Myc correlates with the NPM levels (Guo et al., 
2000; Kim et al., 2000; Neiman et al., 2001; Zeller et al., 2001). A recent report by Li 
and coworkers (2008b) confirms that both endogenous and exogenous NPM directly 
interact with c-Myc and control the expression of endogenous c-Myc target genes at 
the promoter. This finding strengthens the notion that NPM, being a special target of 
the c-Myc pathway, plays an important role in the neoplastic growth of human cancers. 
Altogether, these data implicate NPM as an anti-apoptotic protein that suppresses 
either p53-dependent or -independent apoptosis. It has been suggested that the anti-
apoptotic potential of NPM depends on its expression level and subcellular localization 
(Kondo et al., 1997; Colombo et al., 2002; Bertwistle et al., 2004; Korgaonkar et al., 
2005). Actively dividing cells expressing high levels of NPM are resistant to apoptosis 
induced by UV damage or hypoxia (Nozawa et al., 1996; Subong et al., 1999; Wu and 
Yung, 2002; Li et al., 2004b). Similar to that in other proto-oncogenes, over-
expression of NPM is primarily linked to cell proliferation (Itahana et al., 2003), 
suggesting that NPM as a proto-oncogene promotes cell survival.  
 
Mutations and rearrangements of the NPM1 gene located on human chromosome 5q35 
occur in a variety of hematological disorders (Morris et al., 1994; Redner et al., 1996; 
Falini et al., 2005; Grisendi and Pandolfi, 2005). These rearrangements lead to 
formation of NPM fusion proteins such as NPM-RARα in acute promyelocytic 
leukemia (Redner et al., 1996), NPM-MLF1 in AML (Yoneda-Kato et al., 1996), and 
NPM-ALK in non-Hodgkin’s lymphoma (Morris et al., 1994). In AML, alterations in 
the C-terminus of NPM appear in about 35% of adult patients and result in 
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translocation of NPM to the cytoplasm (Falini et al., 2005). These mutations seem to 
represent tumor-initiating lesions, since they appear before the other AML-associated 
genetic alterations are detectable (den Besten et al., 2005).  
 
2.4 NPM and viruses 
NPM has been involved in the replication cycle of several various viruses. In cells 
infected by adenoviruses, NPM interacts with adenoviral core proteins and relocalizes 
from the nucleolus to speckle-patterned structures representing viral DNA replication 
foci (Walton et al., 1989; Matthews, 2001). Okuwaki and coworkers (2001a) showed 
that NPM is involved in the in vitro replication of the adenovirus DNA. Further 
experiments by Samad and coworkers (2007) confirmed that NPM interacts with 
adenovirus basic core proteins and functions as a chaperone for viral chromatin 
assembly at the late stage of infection. Interestingly, that NPM binds to replication 
proteins of adeno-associated viruses suggests it may play a role in virus amplification 
and virion assembly (Bevington et al., 2007). Several lines of evidence indicate that 
NPM binds to the hepatitis delta antigen, to HTLV-1 Rex, and to HIV-1 Rev proteins 
(Fankhauser et al., 1991; Adachi et al., 1993; Szebeni et al., 1997; Huang et al., 2001). 
A recent study by Lee and coworkers (2009b) identified NPM as a host factor that 
interacts with HBV core protein 149 (Cpl49). Moreover, phosphorylation by caseine 
kinase 2 (CK2) enhances NPM affinity to the NLS sequences derived from the SV40 
large T antigen and the HIV Rev protein (Szebeni et al., 1995; Szebeni et al., 1997), as 
well as modulating its molecular chaperoning activity, especially in its interaction with 
target proteins (Szebeni et al., 2003). The chaperone activity of NPM may therefore be 
essential for proper assembly of the replication machinery and for transport of 
ribonucleoprotein particles during viral RNA replication. Interestingly, a recent report 
by Caporale and coworkers (2009) has demonstrated that NPM may be directly 
involved in the shuttling of envelope glycoprotein (JSE-SP) of the Jaagsiekte sheep 
retrovirus. Interaction of NPM with JSE-SP has been suggested to enhance the nuclear 
export of full-length viral RNA and to increase viral particle production by acting at a 
post-translational step in the viral replication cycle. 
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3. Kaposi’s sarcoma herpesvirus (KSHV)  
KSHV, or human herpesvirus-8, is the most recently discovered human herpesvirus. 
This virus emerged in a representational difference analysis, which identified unique 
viral DNA sequences in KS biopsies (Chang et al., 1994). KSHV occurs in all 
subtypes of KS (see below) and also represents the etiological agent of 
lymphoproliferative disorders including PEL and MCD (Ablashi et al., 2002). KSHV 
belongs to the double-stranded DNA (dsDNA) viruses of the gammaherpesvirinae 
subfamily from the same genus as rhadinovirus. It shares sequence homologies with a 
number of other rhadinoviruses (Fig. 4) such as herpesvirus saimiri, rhesus monkey 
rhadinovirus, and murine gamma herpesvirus 68 (Neipel et al., 1997; Jung et al., 1999; 
Searles et al., 1999; Alexander et al., 2000). Similar to other herpesviruses, KSHV 
exists in one of the two life-cycle programs known as latency or lytic replication. In 
the latent infection phase, KSHV persists as a nuclear multicopy episomal DNA 
(Cesarman et al., 1995b; Moore et al., 1996a; Renne et al., 1996a), expressing a small 
subset of genes that allows the virus to maintain its permanent infection (Zhong et al., 
1996). During lytic replication, the complete set of viral genes is expressed, resulting 
in the assembly of new infectious viral particles (Renne et al., 1996b; Miller et al., 
1997). Both latently and lytically infected cells coexist in KS tumors and PEL, with 
latency as their predominant mode of infection (Decker et al., 1996; Zhong et al., 
1996; Staskus et al., 1997). Therefore, the KSHV proteins expressed in both phases 
contribute substantially to persistent infections, as well as to KSHV pathobiology.  
 
3.1 KSHV-associated malignancies 
3.1.1 Kaposi’s sarcoma (KS) 
In 1872, the famed Austro-Hungarian dermatologist Moritz Kaposi (known as Moritz 
Kohn before he converted from Judaism to Catholicism) described in Archiv für 
Dermatologie und Syphilissequences a skin disorder that affected elderly men. Since 
the neoplasms consisted of red and purple plaques or nodules, he expressed his finding 
as a “sarcoma idiopathicum multiplex haemorrhagicum.” Later, KS has been classified 
accordingly to several distinct clinical-epidemiologic settings (Antman and Chang, 
2000). Classic KS is a non-aggressive disorder usually affecting elderly men from the 
Mediterranean region (DiGiovanna and Safai, 1981). This malignancy is not associated 
with HIV co-infection and presents on the lower extremities, usually without disease 
dissemination. Endemic KS affects individuals in sub-Saharan Africa. Although 
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endemic KS is not linked to HIV infection, it is a more aggressive disease than classic 
KS (Taylor et al., 1971; Bayley, 1984; Stein et al., 1994). Iatrogenic KS has been 
described among immunosuppressed patients undergoing solid-organ transplantation 
(Farge, 1993; Margolius et al., 1994; Parravicini et al., 1997b; Shepherd et al., 1997; 
Qunibi et al., 1998; Farge et al., 1999; Cattani et al., 2000). Finally, AIDS-associated 
KS, or “epidemic” KS, is the most common malignancy in patients affected with HIV 
infection. The prevalence of AIDS-associated KS is about 20-fold higher in 
homosexual men than in other HIV-infected risk groups (Kedes et al., 1997a; 
Hermans, 1998). It is generally a highly disseminated cutaneous disease, and the 
advanced stages involve the oral mucosa and visceral organs including the 
gastrointestinal tract and lungs (Beral et al., 1990; Biggar and Rabkin, 1996; Hermans 
et al., 1998).  
 
Early-stage KS lesions, described as patch lesions, are composed of small and irregular 
endothelial cells located around the normal blood vessels. These cells are accompanied 
by an infiltration of inflammatory cells. As the lesions grow, the vascular process 
expands through the skin, and at further stages, spindle-shaped cells appear and form 
vascular channels containing red blood cells (plaque stage). Late-stage KS is 
recognizable, as the nodular stage comprises multiple layers of spindle cells and slit-
like vascular spaces (Ganem, 2006). The spindle cell is considered the KS tumor cell, 
and is thought to be of endothelial origin (Rutgers et al., 1986). Inflammatory and 
spindle cells in KS lesions express cytokines (IFN-γ, TNF-α, IL-1, IL-6), chemokines 
(MCP-1, IL-8) and angiogenic factors (βFGF, VEGF, PDGF) (Weninger et al., 1999; 
Ensoli et al., 2001). In addition, high levels of TGF-β, PDGF-β, CCR5, and their 
receptors (TGF-βR, PDGFR-β) or ligand (CCL5), are reported in spindle cells of KS 
nodular lesions, when compared to normal skin (Wang et al., 2004a). 
 
3.1.2 Primary effusion lymphoma (PEL) 
Primary effusion lymphoma (PEL) is a rare B-cell-non-Hodgkin lymphoma commonly 
found in KSHV- and HIV-positive individuals with advanced AIDS and KS 
(Cesarman et al., 1995a; Ansari et al., 1996; Carbone et al., 1996; Nador et al., 1996). 
PEL can also be found in HIV-negative individuals and may affect patients after solid 
organ transplantation (Jones et al., 1998; Dotti et al., 1999). This type of malignant 
lymphoma predominantly occurs in the peritoneal, pericardial, or pleural body cavities 
as neoplastic effusions without associated solid tumor masses (Carbone and Gaidano, 
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1997; Cesarman and Mesri, 1999; Cesarman, 2002). That most PEL cells are also co-
infected by Epstein-Barr virus (EBV) (Cesarman et al., 1995b; Nador et al., 1996), 
suggests that EBV is an important pathogenic co-factor. EBV infection in PEL is of 
monoclonal origin, and the virus establishes the restricted latency I program (Fassone 
et al., 2000). Symptoms in PEL generally result from accumulation of the malignant 
effusion in a certain body cavity. Patients frequently suffer from dyspnea (as a result of 
pleural or pericardial disease) or abdominal swelling (peritoneal disease). No optimal 
therapy for PEL currently exists, and although some cases respond to cytotoxic 
chemotherapy regimens, the tumor is often resistant to conventional treatment, with 
the majority of the patients dying within a few months (Boulanger et al., 2003; 
Boulanger et al., 2004; Waddington and Aboulafia, 2004; Boulanger et al., 2005). 
Consequently, new therapeutic approaches for PEL with potential clinical applicability 
are urgently needed.  
 
Several studies have provided evidence for rearrangements of immunoglobulin genes 
and somatic hypermutation of the BCL-6 gene in PEL (Drexler et al., 1998; Matolcsy 
et al., 1998; Fais et al., 1999; Gaidano et al., 2000). In addition, PEL cells typically 
express the post-germinal center B-cell marker CD138/syndecan-1 (Gaidano et al., 
1996; Carbone et al., 1997), suggesting that they are in a pre-terminal stage of B-cell 
differentiation close to that of plasma cells. PEL cells usually lack CD20, a marker of 
B-cell differentiation, but display on their surface activation markers such as CD30, 
CD38, CD71, and the epithelial membrane antigen (Carbone et al., 1998; Gaidano and 
Carbone, 2001). Furthermore, expression of several plasma cell markers such as 
VS38c and MUM-1/IRF-4 has also been reported (Carbone et al., 2001).  
 
Interestingly, gene-expression profiling studies have suggested that PEL displays 
attributes bridging immunoblastic and anaplastic large-cell lymphomas (Klein et al., 
2003). These results suggest that PEL tumors consist of a malignant counterpart of B-
cells that have matured but have not reached terminal plasma cell differentiation. Other 
expression profile analyses obtained from PEL have demonstrated overexpression of 
genes responsible for inflammation, cell adhesion, and invasion (Jenner et al., 2003). 
Cytogenetic studies of PEL cells have revealed complex karyotypes but no common 
chromosomal aberrations (Boulanger et al., 2001). However, few cases have presented 
recurrent anomaly such as trisomy 7, trisomy 12, or chromosomal aberrations of bands 
1q21–25 (Gaidano et al., 1999). Similarly to KS lesions, the pattern of KSHV gene 
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expression in PEL is predominantly latent (Zhong et al., 1996; Dupin et al., 1999; 
Katano et al., 2000; Parravicini et al., 2000).  
 
3.1.3 Other KSHV-induced disorders  
MCD is another devastating lymphoproliferative syndrome, manifested by fever, 
anemia, lymphadenopathy, and pulmonary symptoms such as cough and dyspnea 
(Oksenhendler et al., 1996). Evidence shows that a majority of MCD cases are KSHV-
positive, including all HIV-seropositive patients and about half of all HIV-negative 
individuals (Soulier et al., 1995; Gessain et al., 1996; Dupin et al., 1999; Casper, 
2005). The two most important pathologic categories of MCD, the hyaline vascular 
and the plasma-cell types, are based on histologic characteristics of the affected lymph 
nodes (Hall et al., 1989). In contrast to PEL, a majority of MCD lesions are EBV-
negative, and clinical manifestations are in part due cytokine dysregulation. Several 
studies have shown high levels of vIL-6 (Parravicini et al., 1997a; Aoki et al., 2001), 
which controls B-cell differentiation and promotes the expansion of B-cell 
malignancies (Du et al., 2001). Moreover, high expression of IL-10, and of C-reactive 
protein, together with elevated KSHV reactivation, may have implications in the 
MCD’s rapid progression and high fatality (Oksenhendler et al., 2000).  
 
In addition to KS, PEL, and MCD, some evidence also exists for KSHV-positive 
lymphoadenopathies with different clinical, histological, and immunophenotypic 
characteristics in both HIV-positive and -negative patients. Interestingly, a KSHV- and 
EBV-associated disease called germinotropic lymphoproliferative disorder involves 
plasmablasts from the germinal centers of lymph nodes (Du et al., 2002). Dupin and 
coworkers (2000) found a rare disorder called MCD-associated plasmablastic 
lymphoma, characterized by large B-cells with one or two prominent nucleoli. These 
plasmablasts show signs of light chain restriction and may belong to a monotypic cell 
population, a fact which supports the appearance of plasmablastic lymphomas in MCD 
lesions (Dupin et al., 2000). Moreover, KSHV infection is also present in HIV-
associated solid plasmablastic lymphomas which may represent a tissue-based variant 
of PEL (Deloose et al., 2005). The literature also reports several unverified or 
controversial links between KSHV and other lymphomas including multiple myeloma 
and angioimmunoblastic lymphoma (Schulz, 1999; Ablashi et al., 2002).  
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3.1.4 Treatment modalities against KSHV-associated diseases 
Regardless of considerable improvements in understanding of the pathobiology of 
KSHV-associated diseases over the last 16 years, treatment of these disorders at 
present is both toxic and only partially successful. Current data indicate a failure rate 
up to 22% for the highly active anti-retroviral therapy (HAART) in KS (primarily due 
to non-compliance), and suggest that KS represents a continuing health problem for 
years to come (Dittmer et al., 2005). Patients affected by KS, MCD, or PEL are 
usually co-infected with HIV, and control of HIV viral loads is a necessary element of 
their care. Currently, no evidence exists for promising responses in patients with their 
PEL or MCD treated only with HAART therapy, suggesting that in cases of advanced 
KS as well as of MCD and PEL, treatment with HAART alone is insufficient. Patients 
in need of adjunct treatment along with HAART currently receive traditional 
chemotherapy. To treat KS, anthracyclines, anti-mitotic agents, microtubule 
stabilizers, or other chemotherapeutic agents alone or in combination in small clinical 
trials have produced responses ranging from 25 to 90% (Vanni et al., 2006). Overall 
responses depend on tumor burden, associated diseases, and control of primary 
immunodeficiency. Notably a smaller amount of data is available as to treatment of 
PEL and MCD. Treatment of these diseases with regular chemotherapy has been 
restricted by short-lived responses and high mortality (Boulanger et al., 2005; Casper, 
2005). The poor outcome and high toxicity of standard combinatorial chemotherapy 
regimens have prompted researchers to investigate novel therapeutic approaches for 
the treatment of KSHV-associated malignancies.  
 
3.1.4.1 Anti-viral therapies 
The viral load of KSHV in blood has been one of the predictors for progress of KS 
(Smith et al., 1997; Alagiozoglou et al., 2003; Laney et al., 2004; Laney et al., 2007). 
Additionally, findings of one in vitro study suggest that a small amount of lytic KSHV 
infection is essential for the induction and maintenance of KS tumors (Grundhoff and 
Ganem, 2004). MCD is characterized by periodic KSHV lytic replication with high 
viremia in the peripheral blood and a lytic viral gene program (Katano et al., 2000; 
Oksenhendler et al., 2000). PEL usually has a more latent infection program than does 
KS or MCD (Katano et al., 2000), implying that in the prevention of or in therapies 
against KSHV-associated malignancies, an anti-viral treatment designed to abolish 
KSHV lytic replication may represent a viable option. To this end, a series of DNA 
synthesis inhibitors have been developed with variable activity against human 
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herpesviruses (Naesens and De Clercq, 2001). Activity of these drugs is based on the 
ability of a nucleoside analogue to incorporate itself into a growing viral DNA chain 
and thereby terminate the elongation of DNA synthesis. Anti-herpetic inhibitors differ 
in their mechanism of action. Aciclovir and ganciclovir are phosphorylated by the 
herpesvirus thymidine kinase and by UL97 phosphotransferase and act directly on the 
pyrophosphate-binding site of the DNA polymerase. Cidofovir and foscarnet work 
independently of the herpesvirus thymidine kinase and UL97 (Mercorelli et al., 2008). 
Promising therapeutic outcomes in PEL patients have been reported with ganciclovir 
and cidofovir alone or in combination with chemotherapy or HAART (Pastore et al., 
2000; Hocqueloux et al., 2001; Luppi et al., 2005; Crum-Cianflone et al., 2006). 
Intracavitary administration of cidofovir, as well as IFN-α (Boulanger et al., 2003), 
may represent a rational option in patients refractory to standard chemotherapy or in 
patients unable to tolerate more toxic systemic treatments.  
 
Effects comparable to those of PEL have also appeared in MCD patients treated with 
ganciclovir (Casper et al., 2004; Valencia et al., 2005), but not with cidofovir (Berezne 
et al., 2004). Due to the fact that the majority of anti-herpes drugs are most efficient 
against the lytic phase, it has been thought that the effectiveness of anti-viral treatment 
could be enhanced through induction of lytic replication with subsequent blockage of 
virus production. In vitro data suggest that induction of viral reactivation with the 
proteasome inhibitor bortezomib, or with valproic or glycyrrhizic acid may render 
tumor cells more sensitive to the anti-viral therapy (Brown et al., 2005; Curreli et al., 
2005; Klass and Offermann, 2005).  
 
3.1.4.2 Therapies under investigation  
KS is a highly vascularized tumor, and expression of the human vascular endothelial 
growth factor (VEGF) is crucial for KS tumorigenesis (Cornali et al., 1996; Masood et 
al., 1997; Nakamura et al., 1997). Clinical studies with the first approved VEGF 
inhibitors reveal their moderate toxicity and minimal efficacy in KS tumors (Pluda et 
al., 1993; Eckhardt et al., 1996). Intriguingly, later work on an innovative anti-sense 
oligonucleotide to VEGF (VEGF-AS) has led to an impressive decrease in VEGF 
plasma levels and a total remission of KS in one patient refractory to HAART and to 
chemotherapy (Levine et al., 2006). Despite the fact that targeting VEGF is a 
promising therapeutic modality, inhibition of other signaling pathways involved in KS 
has also been under exploration. Platelet-derived growth factor receptor (PDGFR) and 
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c-kit proto-oncogene are both reported to be overexpressed in KS (Werner et al., 1990; 
Sturzl et al., 1992; Pistritto et al., 1994; Moses et al., 2002). Imatinib, a tyrosine kinase 
inhibitor, inhibits activity of multiple tyrosine kinases such as Bcr-Abl, PDGFR, and c-
kit (Druker et al., 1996; Heinrich et al., 2000). To assess the efficacy of imatinib for 
KS, patients with advanced AIDS-associated KS were treated with the drug. 
Intriguingly, among 10 individuals, a clinical response occurred in four (Koon et al., 
2005). An additional promising therapeutic strategy for KS may be the inhibition of 
matrix metalloproteinases (MMPs), endopeptidases involved in angiogenesis through 
degradation of extracellular matrix (Egeblad and Werb, 2002). MMPs are also highly 
expressed in KS lesions, suggesting that their role in tumorigenesis most likely is in 
facilitating the invasion of tumor cells into the basement membrane (Benelli et al., 
1994; Blankaert et al., 1998). Clinical trials in KS patients with MMP inhibitors 
similar in structure to tetracycline have resulted in a 40% response rate. Importantly, 
these inhibitors were also well tolerated and had an anti-tumor potential in patients 
with AIDS-associated KS (Dezube et al., 2006). 
 
One line of therapeutic approaches with great potential for KSHV-induced diseases 
perhaps could rely on targeting the NF-κB pathway through proteasome inhibition. 
NF-κB is constitutively active in those PEL cells (Keller et al., 2000; Guasparri et al., 
2004) sensitive to BAY-117082-mediated blockade of NF-κB signaling (Keller et al., 
2000; Keller et al., 2006). Interestingly, bortezomib, an inhibitor of the NF-κB 
pathway, induces apoptosis in PEL cell lines in vitro (An et al., 2004a). Whether these 
findings can be extended to a clinical setting remains to be seen.  As NF-κB has a 
crucial anti-apoptotic role in cells, it is possible that its pharmacological inhibition 
with the currently available inhibitors may lead to increased apoptosis in normal 
tissues or to unacceptable toxicities due to its inhibition of signaling pathways other 
than NF-κB (Graham and Gibson, 2005). PEL tumors in NOD/SCID mice have also 
been treated with an anti-viral therapy combined with IFN-α. Azidothymidine and 
IFN-α treatment delays tumorigenesis but does not rescue PEL-engrafted SCID mice 
(Wu et al., 2005). Moreover, the pro-apoptotic effect observed for azidothymidine and 
IFN-α in PEL cells occurs through the concomitant activation of TRAIL and the 
blockade of NF-κB (Toomey et al., 2001; Ghosh et al., 2003), which may enhance the 
possibility of their non-specific apoptotic effect.  
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Several studies have suggested that an Akt-signaling downstream effector termed 
tuberous sclerosis complex-mammalian target of rapamycin (TSC-mTOR), is a key 
intracellular pathway controlling pathological angiogenesis and tumor development of 
endothelial origin (Montaner et al., 2001; Phung et al., 2006; Sodhi et al., 2006). 
Activation of the PI3K/Akt/mTOR pathway by the KSHV lytic protein vGPCR (viral 
G protein-coupled receptor) plays a fundamental role in KS development. 
Interestingly, a highly potent and specific inhibitor from the rapamycin family can 
inactivate vGPCR oncogenesis in vitro and in vivo (Sodhi et al., 2006). Rapamycin 
(sirolimus) has been used for transplant recipients affected by iatrogenic KS 
(Campistol and Schena, 2007), as well as for patients with the classic form of the 
disease (Guenova et al., 2008; Merimsky et al., 2008). Interestingly, Sin and 
coworkers (2006) have demonstrated that rapamycin inhibits PEL growth in vitro and 
in vivo. Another report has suggested that rapamycin induces only a preliminary 
response; it does not eradicate PEL. The hypoxic environment of the body cavity is 
implicated in initiation of cytokine-mediated escape mechanisms leading to disease 
development (Gasperini and Tosato, 2009). 
 
3.2 KSHV latency program  
KSHV has a large, double-stranded DNA genome that forms a closed circular episome 
upon entry into the nucleus. During productive replication, viral progeny DNA is 
ultimately synthesized as linear, single-unit genomes destined for incorporation into 
independent virions (Renne et al., 1996a). During latent infection, KSHV encodes only 
a minority of the nearly 100 genes in the genome (Zhong et al., 1996). Among the 
viral proteins expressed in latently infected cells are: (a) a latency-associated nuclear 
antigen (LANA), (b) a viral homolog of cyclin D2 (viral cyclin, v-cyclin), and (c) an 
anti-apoptotic viral FLICE-inhibitory protein (v-FLIP). These proteins are encoded by 
the open reading frames ORF73, ORF72, and ORF71, respectively (Fig. 4), and they 
belong to a common polycistronic transcriptional unit, identified as the latency 
transcript (LT) cluster (Dittmer et al., 1998; Sarid et al., 1998; Talbot et al., 1999).  
In latent infection, genes in the LT cluster are transcribed from a constitutively active 
promoter. This results in an unspliced, full-length 5.8-kb transcript or an alternatively 
spliced 5.4-kb mRNA containing ORF71, ORF72, and ORF73. Additionally, a short 
1.7-kb transcript is formed by mRNA splicing and contains only ORF71 and ORF72. 
The major translation product of the longer (tricistronic) mRNA is LANA, whereas  
v-cyclin and v-FLIP are primarily translated from the shorter (bicistronic) transcript, 
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the latter by utilizing an internal ribosome entry site at the end of ORF72 (Bieleski and 
Talbot, 2001; Grundhoff and Ganem, 2001; Low et al., 2001). Moreover, a rare splice 
variant, a short 1.1-kb mRNA that contains exclusively ORF71, is detectable in PEL 
cells (Grundhoff and Ganem, 2001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. KSHV genomic open reading frames (ORFs). Arrows represent individual ORFs, and the 
dots represent the KSHV-encoded microRNAs. ORFs unique to KSHV are indicated by black arrows. 
ORFs common to rhadinoviruses are indicated by red arrows, ORFs common to other γ-herpesviruses 
by light blue arrows, and ORFs common to most herpesviruses by green arrows. TR denotes terminal 
repeats. Alternative names mentioned in this thesis for some of these unique KSHV genes appear in 
parentheses (Adapted and modified from Wen and Damania, 2010). 
 
During the latent phase of KSHV infection, other latent genes are also expressed from 
the viral episome. The K12 gene, encoding Kaposin (Muralidhar et al., 1998; Sadler et 
al., 1999), is expressed at low levels during latency. K12 is separated from the LT 
cluster by a 4-kb intergenic sequence (Fig. 4), which is the biggest coding gap in the 
unique region of the KSHV genome. Interestingly, 10 of the 12 recently discovered 
KSHV microRNAs (miRNAs, Fig. 4) are positioned in this intergenic region (Cai et 
al., 2005; Pfeffer et al., 2005; Samols et al., 2005). The two other miRNAs, miR-K10 
and miR-K12, are located within the K12 coding region and within the 3’-UTR of K12 
(Fig. 4), respectively (Grundhoff et al., 2006). Viral interferon regulatory factor 3 
(vIRF-3, LANA2), encoded by the K10.5 gene, is another protein classified as a latent 
KSHV gene product (Lubyova and Pitha, 2000), and its expression seems to be 
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restricted to KSHV-infected hematopoietic tissues, including PEL and MCD; vIRF-3 
is not detectable in KS lesions. 
 
3.2.1 KSHV latency-associated nuclear antigen 
LANA, initially termed latent nuclear antigen, is one of the major proteins expressed 
during KSHV latency (Gao et al., 1996a; Kedes et al., 1997b).  It is a multi-domain 
protein that possesses multifunctional properties. The LANA protein is 222 to 234 kDa 
in size, consisting of 1,162 aa. It produces a typical speckled nuclear signal upon 
indirect immunofluorescence with LANA-specific antibodies (Gao et al., 1996a; Gao 
et al., 1996b; Kedes et al., 1996). LANA consists of three domains: (a) an N-terminal 
domain rich in Ser/Thr, Pro, and basic residues, (b) an internal repeat domain, which is 
highly polymorphic and abundant in Glu, Asp, Gln, and Leu, and (c) a C-terminal 
domain where charged and hydrophobic residues are located (Gao et al., 1999; Zhang 
et al., 2000). 
 
3.2.1.1 LANA and episome maintenance 
Due to the fact that the KSHV genome encodes no homologs of centromeres, there 
exists a need for an alternative mode of episome replication, segregation, and latency 
maintenance in the daughter cells. LANA has been shown to bind episomes and 
colocalize with KSHV (Ballestas et al., 1999; Komatsu et al., 2004; Tetsuka et al., 
2004), and to tether the KSHV episome to the host cell chromosomes (Ballestas et al., 
1999; Cotter and Robertson, 1999; Szekely et al., 1999; Mattsson et al., 2002; 
Shinohara et al., 2002; Barbera et al., 2006). This further shows LANA to be a key 
player in episomal persistence. Additionally, expression of LANA has been 
demonstrated as sufficient for replication and segregation of viral minigenomes, i.e. 
plasmids with terminal repeat elements (Garber et al., 2001; Hu et al., 2002; 
Grundhoff and Ganem, 2003). Episomal segregation in mitosis, which guarantees that 
identical numbers of KSHV episomes are divided into every daughter cell, is also 
LANA-dependent (Ballestas et al., 1999; Hu et al., 2002; Grundhoff and Ganem, 
2003). Consequently, a KSHV mutant, BAC36-ΔLNA, with its LANA disrupted by 
transposon-based mutagenesis with a KSHV BAC clone, BAC36, is inefficient in the 
establishment and maintenance of latency in mammalian cells (Ye et al., 2004).  
 
LANA interacts with the core histones H2A and H2B to tether episomes to the 
nucleosome during mitosis and interphase (Barbera et al., 2006). Both N- and  
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C-terminal LANA domains bind to host chromosomes. However, the C-terminus is 
insufficient to maintain episome persistence alone in the N-terminus mutants (Piolot et 
al., 2001; Krithivas et al., 2002; Shinohara et al., 2002; Barbera et al., 2004; Barbera 
et al., 2006). On the other hand, the LANA C-terminus is essential for its 
oligomerization, and current data imply that efficient tethering of the KSHV episome 
depends on LANA oligomerization (Schwam et al., 2000; Viejo-Borbolla et al., 2005; 
Verma et al., 2006). Moreover, to generate the best possible conditions for episomal 
replication, LANA also interacts with multiple chromosome-binding and origin 
recognition complex (ORCs) proteins such as Brd2/RING3, ORC2, HBO1, CBP, and 
also cohesins (Stedman et al., 2004; Verma et al., 2006; Stedman et al., 2008).  
Of note, a particular 32-bp sequence upstream of LANA binding site 1, referred to as 
replication element, associates with ORC2. Ectopic expression of LANA multiplies the 
number of copies of chromatin-bound DNA of replication elements, suggesting that 
LANA is essential for the recruitment of ORCs and may contribute to the stabilization 
of the replication protein complexes at the replication element site (Verma et al., 
2007). These data clearly indicate that LANA not only tethers the episome to the 
chromosomes but also actively takes control of cellular proteins to support the virus in 
its episomal replication process.  
 
3.2.1.2 LANA and regulation of viral and cellular gene transcription 
Additional to its role in episomal maintenance and segregation, LANA also modulates 
cell proliferation, transformation, apoptosis, and immune responses. LANA takes 
action as a direct or indirect transcriptional repressor or even sporadically as a 
transcriptional activator contributing to latent infection. A study by Radkov and 
coworkers (2000) showed that LANA with Hras may induce transformation in primary 
rat fibroblasts. Moreover, LANA overexpression enhances the lifespan and cellular 
proliferation of primary HUVEC cells (Watanabe et al., 2003). Importantly, sole 
overexpression of LANA is unable to initiate anchorage-independent growth of 
NIH3T3 cells, demonstrating the importance of other viral genes and factors for 
KSHV-induced malignancies (Watanabe et al., 2003).  
 
The actual mechanism of LANA-mediated cellular transformation has been subjected 
to extensive research. These studies have revealed that LANA acts as a transcriptional 
co-factor and targets the retinoblastoma protein-E2F transcriptional regulatory 
pathway (Radkov et al., 2000). Moreover, LANA activates c-Myc-dependent 
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transcription by promoting its phosphorylation (Liu et al., 2007b). It also interacts with 
Sp1 transcription factor, thus regulating the expression of telomerase (Verma et al., 
2004). Finally, LANA also interacts with and inhibits p53 transcriptional activity and 
p53-dependent apoptosis (Friborg et al., 1999). Suppression of p53 activity by LANA 
has also been linked with genomic instability (Si and Robertson, 2006). Moreover, 
enhanced multinucleation, abnormal establishment of centrosomes, and creation of 
mitotic bridges are reported in mammalian cells with a stable expression of LANA (Si 
and Robertson, 2006).  
 
KS and PEL express high levels of β-catenin (Fujimuro and Hayward, 2003; Fujimuro 
et al., 2003; Fujimuro et al., 2005), which should normally be directed toward 
degradation in the cytoplasm by its negative regulator GSK3β. LANA binds β-catenin 
and subsequently translocates GSK3β to the nucleus, thus preventing negative 
regulation of β -catenin. β -catenin then targets gene products that have essential 
functions in cell cycle progression and cell proliferation such as Cyclin D1, Myc, and 
Jun (Fujimuro et al., 2003). Moreover, high expression of LANA promotes the 
expression of IL-6 by activating the AP-1 pathway (An et al., 2002). This may lead to 
consequent activation of STAT3 signaling, and LANA ability to interact with STAT3 
enhances STAT3-induced transcription (Muromoto et al., 2006). Furthermore, LANA 
activates the AP-1 pathway by itself, through binding to Jun to facilitate the assembly 
of Jun-Fos heterodimers (An et al., 2004b).  
 
Regulation and control of transcription by LANA may involve multiple mechanisms. 
LANA may repress transcription in vitro through either the C- or the N-terminus 
domain when fused to a heterologous DNA-binding motif (Schwam et al., 2000). 
Another possible mechanism of transcriptional repression is recruitment and binding to 
members of the mSin3 transcriptional repressor complex (Krithivas et al., 2000). 
Additionally, LANA actively represses the transcriptional activity of the ATF4/CREB 
complex (Lim et al., 2000). Another finding is that LANA represses both: CBP 
transcriptional activation as well as histone acetyltransferase (HAT) activity (Lim et 
al., 2001). LANA is responsible for enhanced expression of Id-1 (Tang et al., 2003), 
which plays an important role in cell cycle regulation and differentiation (Benezra et 
al., 1990). LANA also regulates transcriptional repressor KLIP1 and alleviates its 
transcriptional repression effects (Zhang et al., 2001; Pan et al., 2003). Lastly, LANA 
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also has the ability to auto-regulate its own promoter and to activate its own 
transcription (Jeong et al., 2004). 
 
3.2.1.3 LANA and repression of lytic replication 
As a final point, LANA-mediated transcriptional control has strong implications for 
viral latency. LANA interacts with RBP-Jk or Sp1 transcription factors and modulates 
the expression of replication transcriptional activator (RTA) (Verma et al., 2004; Lan 
et al., 2005b). Notably, LANA may interact directly with RTA, and it suppresses 
activation of the RTA promoter (Lan et al., 2004; Lan et al., 2005a). Interestingly, this 
ability is antagonized by Pim-1 and Pim-3 kinases (Cheng et al., 2009). Furthermore, 
LANA regulates viral gene expression through epigenetic modifications of the viral 
genome (Lu et al., 2006). Viral genes have been regulated in a LANA-dependent 
manner via its interaction with SUV39H1 and its recruitment of HP-1. When histone-
H3 is being methylated by SUV39H1, HP-1 is recruited and forms inactive 
heterochromatin (Sakakibara et al., 2004). These events lead to condensation of the 
viral episome, and as a result, to transcriptional supression of all viral genes except 
those within the latency locus (Sakakibara et al., 2004).  
 
3.2.2 KSHV-encoded cyclin (v-cyclin) 
The KSHV gene ORF72 encodes a protein of 257 aa with an approximate molecular 
weight of 29 kDa. The product of this gene is called v-cyclin, K-cyclin, or KSHV-
cyclin, and has 32% identity and 54% similarity to mammalian cyclin D2 (Li et al., 
1997). The v-cyclin preferably binds to and activates CDK6 and only weakly 
associates with CDK2, CDK3, CDK4, CDK5, and CDK9 (Godden-Kent et al., 1997; 
Li et al., 1997; Platt et al., 2000; Chang and Li, 2008). Interaction of v-cyclin with its 
catalytic subunit CDK6 is a prerequisite to form a powerful, constitutively active 
kinase complex (Van Dross et al., 2005), which is not regulated by the CDK-activating 
kinase (Kaldis et al., 2001). This kinase complex phosphorylates a broad range of 
substrates including histone H1 and retinoblastoma protein Rb (Godden-Kent et al., 
1997; Li et al., 1997), p27KIP1 (Swanton et al., 1997; Ellis et al., 1999; Mann et al., 
1999), p21CIP1 (Jarviluoma et al., 2006), Id-2 and Cdc25a (Mann et al., 1999), Cdc6 
and ORC1 (Laman et al., 2001), Bcl-2 (Ojala et al., 2000), NPM (Cuomo et al., 2008), 
and caldesmon (Cuomo et al., 2005).  
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Rb operates as a cell-cycle checkpoint protein by binding to the transactivation domain 
of E2F transcription factor to prevent cell cycle progression (Helin et al., 1993; 
Dunaief et al., 1994). Importantly, v-cyclin-CDK6 phosphorylates and inactivates Rb, 
leading to suppression of the Rb-induced cell cycle arrest (Chang et al., 1996; Godden-
Kent et al., 1997). Cell cycle progression is regulated by the consequent activation and 
inactivation of cyclin-dependent kinases (CDKs). Many signals arrest the cell cycle 
through the suppression of CDKs by CKI; v-cyclin-CDK6 overcomes the p27KIP1-
mediated growth arrest (Swanton et al., 1997; Ellis et al., 1999; Mann et al., 1999). 
Overexpression of v-cyclin leads to phosphorylation of p27KIP1 on Thr187 by the 
binary complex v-cyclin-CDK6 and subsequent degradation of p27KIP1 via the 
proteasome-dependent pathway (Ellis et al., 1999; Mann et al., 1999). This may 
nevertheless represent a simpler situation than under in vivo conditions. In contrast to 
other lymphomas, PEL cells express high levels of p27KIP1, and yet proliferate 
actively (Carbone et al., 2000; Jarviluoma et al., 2004). The v-cyclin-CDK6 complex 
prevents p27KIP1 from accomplishing its anti-proliferative function by formation of 
inactive complexes (Jarviluoma et al., 2004). Furthermore, during latent infection, 
phosphorylation of Ser10 on p27KIP1 by the v-cyclin-CDK6 complex leads to 
translocation of p27KIP1 into the cytoplasm and allows PEL cells to proliferate despite 
highly abundant p27KIP1 (III). Of interest, we have found that upon lytic replication, 
v-cyclin-CDK6 directs p27KIP1 to degradation through phosphorylation of Thr187 
(III). In addition to p27KIP1, v-cyclin-CDK6 has been resistant to other CKIs such as 
p21CIP1 and p16INK4 (Swanton et al., 1997; Jarviluoma et al., 2006).  
 
v-cyclin not only has been linked to deregulation of cellular gene expression, it has 
also been shown to suppress STAT3-mediated gene activation (Lundquist et al., 2003) 
and upregulate pro-proliferative genes such as the cyclin A (Duro et al., 1999). Similar 
to many other oncogenes, v-cyclin can also lead to apoptosis or induce cell cycle arrest 
under certain circumstances. It induces apoptosis in the presence of high levels of 
CDK6 (Ojala et al., 1999; Ojala et al., 2000), or stress signals (Verschuren et al., 
2002). To promote apoptosis, v-cyclin-CDK6 phosphorylates and inactivates cellular 
anti-apoptotic protein Bcl-2 (Ojala et al., 2000). Additionally, v-cyclin causes a DNA 
damage response and senescence in endothelial cells (Koopal et al., 2007). 
 
Apoptosis and abnormal cell proliferation triggered by v-cyclin are closely related to 
p53 (Verschuren et al., 2002; Verschuren et al., 2004). Transient expression of v-
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cyclin in MEFs causes p53 accumulation, which contributes to v-cyclin-induced cell 
cycle arrest and apoptosis in MEFs (Verschuren et al., 2002). In a transgenic mouse 
model (Eµ-K-cyclin mice), v-cyclin accelerates lymphomagenesis in p53-/- background 
(Verschuren et al., 2004). These data indicate the existence of a relationship between 
v-cyclin and p53 during tumorigenesis. Additionally, v-cyclin overexpression raises 
MDM2 levels and supports complex formation between MDM2-NPM and p53-NPM 
(Kurki et al., 2004). Interestingly, recent data have suggested CDK9 as a novel v-
cyclin-interacting partner and indicated that the v-cyclin-CDK9 kinase complex 
phosphorylates p53 on Ser33 (Chang and Li, 2008). Any functional consequences of 
this phosphorylation need further investigation, however.  
 
3.3 Molecular events involved in the switch from latency to lytic KSHV 
replication 
A fundamental question concerning the viral life cycle focuses upon the physiological 
stimuli that direct the switch from latent infection to lytic replication, i.e. viral 
reactivation. This switch can be described as a two-event route where: (a) upstream 
actions result in de-repression and induction of the activator genes to initiate the lytic 
cycle and (b) downstream events resulting from a multitude of actions executed by the 
products of the lytic cycle activator genes. Several chemicals and biological stimuli 
can activate the upstream events of viral reactivation. These include phorbol esters, 
which are protein kinase C agonists, histone deacetylase (HDAC) inhibitors, DNA 
methyltransferase inhibitors, anti-immunoglobulins, hypoxia, and also the presence of 
other viruses (Renne et al., 1996b; Miller et al., 1997; Chen et al., 2001; Davis et al., 
2001; Vieira et al., 2001). 
 
3.3.1 Lytic replication phase  
The viral lytic program develops through a sequentially regulated cascade of gene 
expression. These lytic cycle-specific genes (Table 1) can be grouped into three 
categories based on their expression kinetics: immediate-early (IE), delayed-early 
(DE), and late genes (L). After primary infection or upon reactivation from latency, 
expression of IE genes begins instantly. These genes are critical for the start of viral 
transcription and usually encode for regulatory proteins. RTA is the gene product of 
ORF50, the major IE transcript of KSHV, which is necessary and sufficient to force 
the switch from latency to lytic gene expression (Sun et al., 1998). Expression of the 
RTA mRNA is insensitive to protein synthesis inhibitors like cycloheximide, 
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indicating that de novo protein production is not required for reactivation (Gradoville 
et al., 2000; Ye et al., 2007). DE genes are expressed after the IE, but prior to viral 
DNA synthesis. Inhibitors of viral DNA synthesis such as phosphonoacetic acid or 
ganciclovir (GCV) do not affect expression of these genes. Late lytic genes whose 
expression is inhibited by phosphonoacetic acid or GCV usually appear after 30 hours 
post-induction (Sun et al., 1999; Zhu and Yuan, 2003). Examples of genes from these 
groups are in Table 1. 
 
Table 1. Classification of KSHV lytic genes 
Group     Gene and gene description Reference  
IE ORF50/RTA (R transcriptional activator) (Sun et al., 1999)  
IE ORF45 (virion phosphoprotein) (Zhu et al., 1999)  
IE ORF29 (putative ATPase subunit of terminase) (Saveliev et al., 2002)  
IE ORF4.2/KCP (complement control protein) (Zhu et al., 1999)  
IE ORF K3 (E3 ubiquitin ligase) (Sun et al., 1999)  
IE ORF K5 (E3 ubiquitin ligase) (Sun et al., 1999)  
DE ORF16/vBcl-2 (bcl-2-like inhibitor of apoptosis) (Sun et al., 1999)  
DE ORF49 (c-Jun-mediated transcriptional activator) (Gonzalez et al., 2006)  
DE ORF57 (DNA polymerase catalytic subunit) (Lukac et al., 2001)  
DE ORF59 (DNA polymerase processivity subunit) (Chan and Chandran, 
2000) 
 
DE ORF74/vGPCR (viral G protein-coupled receptor) (Kirshner et al., 1999)  
DE ORF K1 (ITAM signal-transducing membrane glycoprotein) (Jenner et al., 2001)   
DE ORF K2/v-IL6 (interleukin-6) (Sun et al., 1999)  
DE ORF K4/vCCL-2 (interleukin 8-like CC chemokine) (Sun et al., 1999)  
DE ORF K8 (K-bZIP transcription factor) (Lukac et al., 2001)  
DE ORF K9/vIRF1 (interferon regulatory factor) (Chen et al., 2000)  
DE ORF K15 (signal-transducing membrane protein) (Choi and Nicholas, 2010)  
L ORF65/sVCA (small viral capsid antigen)   (Lin et al., 1997)  
L ORF51/K8.1 (envelope glycoprotein) (Chandran et al., 1998)  
L ORF25/MCP (major capsid protein)   (Ascherl et al., 1999)  
L ORF17 (minor capsid scaffold protein) (Unal et al., 1997)  
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3.3.2 ORF50/RTA: master regulator of the latent-lytic switch 
The KSHV latent-lytic switch is triggered by a number of factors that stimulate the 
expression of the major lytic switch protein, RTA. Expression of RTA is absolutely 
required to execute the lytic program resulting in tightly regulated expression of viral 
proteins, replication of viral DNA, assembly and release of viral particles, and host cell 
death (Lukac et al., 1998; Sun et al., 1998; Lukac et al., 1999).  During the latency, 
only a few genes are transcribed, whereas expression of RTA is highly repressed 
(Katano et al., 2001a). Several lines of evidence suggest that epigenetic modifications 
and chromatin remodeling are actively involved in this repression (Lu et al., 2003). 
Epigenetic modifications including DNA methylation control gene expression during 
development and play important roles in cancer by transcriptional silencing of 
essential growth controllers (Baylin, 2005). It has been suggested that 
hypermethylation of the RTA promoter controls its expression and subsequently 
regulates the KSHV latent-lytic switch (Chen et al., 2001). Moreover, high 
methylation at the RTA promoter region in latency promotes the association of 
transcriptional repressors and HDACs (Shamay et al., 2006). Additionally, other 
chromatin modifications such as acetylation, and modifications in the chromatin-
binding proteins (Lu et al., 2003) influence chromatin structure and, together with 
DNA methylation, may also control transcription of the ORF50 gene.  
 
Viral reactivation can be induced by chemicals including sodium butyrate (NaB) and 
12-O-tetradecanoylphorbol-13-acetate (TPA) (Renne et al., 1996b; Miller et al., 1997). 
NaB is an HDAC inhibitor (Boffa et al., 1978), whereas TPA is an inducer of HAT 
(Masumi et al., 1999). Deacetylation reverses the acetylation process and leads to 
establishment of strongly packaged nucleosomes, which are inaccessible to 
transcription factors (Yang et al., 1996). Therefore, both NaB and TPA affect the 
acetylation status of the RTA promoter, and thus KSHV lytic replication, by distinct 
mechanisms. TPA induces the KSHV lytic cycle by activating a variety of 
transcription factors and enhancing their DNA-binding activity (Wang et al., 2004b), 
whereas successful activation by NaB critically depends on binding of the Sp1 
transcription factor to the butyrate-responsive element in the promoter of ORF50  
(Ye et al., 2005). Subsequently, treatment with NaB enhances recruitment of Sp1 with 
its co-activator CBP, which possesses HAT activity and physically interacts with RTA 
(Gwack et al., 2001; Lu et al., 2003). Following the initial activation, RTA is recruited 
to its responsive elements through direct interaction with the Notch signaling pathway 
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transcription factor RBP-Jk (Liang and Ganem, 2004; Chang et al., 2005a; Chang et 
al., 2005b). 
 
RTA-mediated control of RBP-Jk activity from its repressed state to its activation is 
critical for further lytic gene expression (Liang and Ganem, 2003). To this end, RTA 
recruits the chromatin-remodeling complex SWI/SNF and the TRAP/mediator 
coactivator to its downstream viral promoters, a recruitment essential for RTA-
dependent viral gene expression (Gwack et al., 2003). As reviewed in 3.2.1, LANA 
takes control of RTA activity by direct binding to the ORF50 promoter as well as 
through protein-protein interactions. Treatment of PEL cells with NaB leads to an 
increase in the lysine acetylation of LANA and its dissociation from the ORF50 
promoter. Subsequent removal of LANA from Sp1 allows Sp1 and ORF50 to interact, 
and leads to transcriptional activation (Lu et al., 2006). These findings indicate that 
regulation of the latent-lytic switch depends on an intimate interplay between viral 
RTA, cellular HAT, and HDAC activities, plus a variety of host factors that regulate 
chromatin methylation and acetylation.  
 
3.3.2.1 Downstream targets of RTA 
RTA has also been demonstrated to control and transactivate a number of downstream 
lytic genes such as K1 (Bowser et al., 2002; Bowser et al., 2006), K2/vIL-6 (Deng et 
al., 2002), K3 (Chang et al., 2005a), K5 (Haque et al., 2000), K9/vIRF-1 (Ueda et al., 
2002), K8 (Lukac et al., 1999), K15 (Wong and Damania, 2006), ORF57 (Lukac et al., 
1999), ORF74/vGPCR (Jeong et al., 2001), and others. RTA downstream targets are 
activated through two distinctive strategies: RTA either directly recognizes RTA-
responsive elements in the promoters of its target genes, or it interacts with cellular or 
viral factors bound to the promoters (Song et al., 2003; Chang et al., 2005a; Chang et 
al., 2005d). Although no significant homology has emerged among the RTA-
responsive viral promoters, an evaluation of the K8 RTA-responsive elements with 
other viral RTA-responsive elements confirms a striking pattern of A/T triplets located 
within a frequency of 10 to 20 bp (Liao et al., 2003). The multiplicity of RTA-binding 
sites suggests that the activation of RTA target gene promoters is a consequence of 
RTA interaction with factors that mediate the DNA-transcriptional complex 
interaction. These cellular factors may involve NF-κB (Roan et al., 2002) or TATA-
binding protein, as has been demonstrated for the K1 promoter (Bowser et al., 2006). 
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RTA also regulates ORF74 (vGPCR) and K14 (vOX2) genes by an IFN-stimulated 
response element-like sequence in the promoter region (Zhang et al., 2005a).  
 
3.3.3 Diverse cellular factors involved in KSHV reactivation 
Many factors regulate the expression of RTA and imply KSHV lytic replication. 
Recognition of cellular factors that cooperate with RTA in the switch from KSHV 
latency to lytic replication is a prerequisite in understanding the virus life cycle and its 
pathobiology. KSHV lytic reactivation has been reported to occur as a response to a 
variety of stimuli such as TPA (Renne et al., 1996b; Sarid et al., 1998), NaB (Miller et 
al., 1997), ionomycin (Lukac et al., 1999), 5-azacytidine (Chen et al., 2001), IL-6 
(Chang et al., 2000; Chatterjee et al., 2002), IFN-γ (Blackbourn et al., 2000), hypoxia 
(Davis et al., 2001), and co-infection with other viruses (Harrington et al., 1997; Vieira 
et al., 2001). Induction of viral reactivation by TPA involves protein kinase C 
signaling and the calcium-dependent calcineurin pathway (Zoeteweij et al., 2001; 
Deutsch et al., 2004). It has also been shown that epinephrine and norepinephrine are 
capable of reactivating KSHV from latency through activation of protein kinase A 
signaling (Chang et al., 2005c). MEK/ERK, JNK, and p38 MAP kinase pathways have 
also been suggested to be involved in the latent-lytic switch (Cohen et al., 2006; Ford 
et al., 2006; Pan et al., 2006). These results have been further confirmed, and in 
addition all three MAPK pathways are demonstrated to mediate KSHV reactivation 
through AP-1, which associates with the RTA promoter, leading to expression of RTA 
protein, and to activation of the lytic program (Xie et al., 2008). Moreover, AP-1, the 
cellular complex of c-Jun and c-Fos, mediates the transcription of MAPK target genes 
(Wang et al., 2004b). Both the RTA promoter and the origin of lytic replication have 
AP-1 binding sites (Wang et al., 2004b), which allow the virus to reactivate promptly 
if cellular conditions are unfavorable for the latency. Intriguingly, KSHV utilizes 
dopamine receptors with the associated MAPK pathways to detect and transmit stress 
signals for reactivation (Lee et al., 2008). By using a gain-of-function kinome screen 
to identify novel kinases inducing viral reactivation, a recent study has revealed that 
Ser/Thr kinase Pim-1 induces KSHV reactivation (Varjosalo et al., 2008). This finding 
was further extended to Pim-3, and phosphorylation of LANA by these kinases was 
established as a mechanism that disables LANA-dependent repression of viral 
transcription (Cheng et al., 2009). Recently, inhibition of the phosphatidylinositol 3-
kinase-(PI3K)-Akt pathway has been reported to enhance KSHV lytic replication and 
facilitate reactivation from latency (Peng et al., 2010). 
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The primary target of the Notch signaling pathway RBP-Jk mediates RTA-dependent 
activation of KSHV lytic genes (Liang et al., 2002). Interestingly, high expression of 
intracellular-activated Notch1 reactivates KSHV from latency in PEL cells (Lan et al., 
2006). The CCAAT/enhancer-binding protein-α (C/EBPα) was the first discovered 
member of the leucine zipper family of transcription factors, which comprises c-Jun, c-
Fos, ATF, and CREB (Landschulz et al., 1988). Notably, C/EBPα is expressed at the 
early stages of KSHV reactivation (Wang et al., 2003a), and its overexpression has 
been confirmed to activate the RTA promoter in reporter gene assays (Wang et al., 
2003b). Another basic leucine zipper transcription factor, the X-box binding protein 1, 
has also been identified as inducing lytic replication in PEL cells through 
transactivation of the RTA promoter (Wilson et al., 2007; Yu et al., 2007). Moreover, 
X-box binding protein 1 has recently been shown to cooperate with hypoxia-inducible 
factor 1α to induce RTA expression, leading to the production of infectious viral 
particles under hypoxia (Dalton-Griffin et al., 2009).  
 
The role of the NF-κB signaling pathway in the KSHV lytic replication program is 
rather controversial. NF-κB is constitutively active in PEL cells and promotes their 
survival (Keller et al., 2000). One report by Brown and coworkers (2003) has shown 
that inhibition of NF-κB results in elevated lytic protein synthesis in both PEL cells 
and de novo KSHV-infected epithelial cells. In contrast, Sgarbanti and coworkers 
(Sgarbanti et al., 2004) have demonstrated that induction of NF-κB signaling is 
required for the production of new infectious virions from TPA-induced PEL cells. 
The initial host defense against viral pathogens is based on the innate immune system. 
This includes a variety of cellular elements and humoral factors in which the type I 
IFN (IFN-α/β) plays a fundamental role (Muller et al., 1994). Wang and coworkers 
(2005a) have demonstrated that the cellular IRF-7 antagonizes KSHV lytic replication 
by competing with RTA for binding to the RTA-responsive element in the ORF57 
promoter. Subsequently, RTA, which possesses E3-ubiquitin ligase activity, targets 
IRF-7 for proteasome-mediated degradation (Yu et al., 2005). Inflammatory cytokines 
including IFN-γ and oncostatin M have also been demonstrated to induce viral lytic 
replication (Monini et al., 1999; Blackbourn et al., 2000; Chang et al., 2000; Mercader 
et al., 2000), the detailed mechanism remains unresolved, however.  
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3.4 Key aspects of lytic replication for KSHV pathogenesis 
Although latency plays an important role in persistent viral infection, lytic replication 
has also been suggested as a key event in the development and progression of KSHV-
induced malignancies. Indeed, KS expansion from the asymptomatic to the fully 
established disease has been linked with increased KSHV viral loads in peripheral 
blood mononuclear cells (Moore et al., 1996b). Moreover, high viral loads are 
detectable upon appearance of new KS lesions and are associated with disease severity 
(Whitby et al., 1995; Brambilla et al., 1996; Campbell et al., 2000; Pellet et al., 2002; 
Quinlivan et al., 2002; Campbell et al., 2003; Engels et al., 2003; Song et al., 2004; 
Guttman-Yassky et al., 2007; Laney et al., 2007; Mancuso et al., 2008). Furthermore, 
treatment of patients dually infected with KSHV and HIV-1 with GCV, which is active 
against KSHV lytic replication, results in a decrease in AIDS-related KS incidence 
(Martin et al., 1999).  
 
Infected cells are predominantly latent; however, a minority of tumor cells undergo 
spontaneous lytic reactivation (Zhong et al., 1996; Staskus et al., 1997; Reed et al., 
1998; Staskus et al., 1999). Importantly, one in vitro study has suggested that a small 
amount of lytic KSHV infection is essential for the induction and maintenance of KS 
tumors (Grundhoff and Ganem, 2004). Several lines of evidence have illustrated how 
lytic replication is associated with expression of a number of viral-encoded cellular 
homologs with identifiable cytokine and cytokine-receptor signal transduction 
properties. These molecules may possibly mediate autocrine and paracrine signaling 
during tumor development. One of these homologs, termed vGPCR increases 
endothelial cell proliferation and promotes survival by activating MAPK, PI3-kinase, 
and p38 MAP pathways (Sodhi et al., 2000; Smit et al., 2002), as well as by 
stimulating NF-κB signaling (Schwarz and Murphy, 2001). Therefore, vGPCR acts as 
an important factor in promoting endothelial cell growth and transformation 
(Arvanitakis et al., 1997; Bais et al., 1998; Couty et al., 2001; Pati et al., 2001; 
Grisotto et al., 2006). Interestingly, ectopic expression of vGPCR in endothelial cells 
leads to activation of VEGF receptors and to cell immortalization. These cells actively 
proliferate and form foci in culture as well as forming tumors in nude mice 
independently of VEGF stimulation (Bais et al., 2003; Grisotto et al., 2006). 
Furthermore, mice expressing the vGPCR transgene develop highly angioproliferative 
tumors resembling KS lesions (Yang et al., 2000; Jensen et al., 2005). vGPCR also 
directly enhances expression of a variety of other cytokines and growth factors 
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including IL-4 and GM-CSF (Pati et al., 2003), IL-6 and TNF-α (Schwarz and 
Murphy, 2001), Gro-α (Montaner et al., 2004), and CCL-2 (Choi and Nicholas). These 
results suggest that vGPCR contributes to tumorigenesis through autocrine and 
paracrine mechanisms, which are essential for tumor cell proliferation, 
neoangiogenesis, and inflammation.  
 
The KSHV-encoded homolog of IL-6 also promotes cell survival and proliferation 
(Nicholas et al., 1997; Aoki et al., 1999; Hideshima et al., 2000). Moreover, vIL-6 
stimulates production of VEGF and cellular IL-6, thus playing an important role in 
neoangiogenesis and hematopoiesis (Mori et al., 2000; Liu et al., 2001). Interestingly, 
it modulates the host’s immune response and protects PEL cells from IFN-α-induced 
antiviral defence (Chatterjee et al., 2002). Finally, it may also be the case that 
expression of viral lytic homologs of human anti-apoptotic proteins plays an important 
role in the development of KSHV-induced malignancies. Being a homolog of the 
human anti-apoptotic protein Bcl-2, vBcl-2 inhibits apoptosis (Cheng et al., 1997; 
Matta and Chaudhary, 2004). Moreover, it occurs at high levels in both monocytes and 
spindle cells in KS lesions (Sarid et al., 1997; Widmer et al., 2002). Additionally, the 
K7 gene encodes a viral lytic inhibitor of apoptosis (vIAP), a homolog of cellular 
protein survivin-DeltaEx3 (Wang et al., 2002), which prevents apoptosis by bridging 
the mitochondrial protein Bcl-2 and caspase-3 to suppress caspase-3 function (Wang et 
al., 2002). In addition, it promotes cytosolic Ca2+ entry and protects against 
mitochondrial damage (Feng et al., 2002). Taken together, control of the latent-to-lytic 
switch in KSHV-infected cells, and the expression of lytic gene products may both 
play fundamental roles in the pathogenesis of KSHV-induced diseases. 
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AIMS OF THE STUDY  
 
Unlike in many other human cancers, in KSHV-induced lymphomas, TP53 gene 
mutations are rare, and the majority of these tumors have retained wt p53. This study 
was undertaken to elucidate the functional consequences and mechanisms of p53 
restoration by the small-molecule inhibitor of MDM2 in KSHV lymphomas (PELs) in 
vitro, ex vivo, and in vivo. Subsequently, an intriguing and unexpected finding of 
compromised apoptotic response in some of the mice redirected our attention toward 
discovery of the mechanism behind this phenomenon. As a second aim, we sought to 
identify novel in vivo interaction partners for the KSHV latent gene product v-cyclin, 
and to reveal biological consequences of such an interactions.  
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MATERIALS AND METHODS  
 
The materials and methods of this study are listed below, with detailed descriptions in 
the original publications, here referred to by Roman numerals.  
 
Table 2. Cell lines used in this study 
Cell line     Description Source or reference 
Used  
in 
BC-1 Human primary effusion lymphoma cell line 
(PEL); KSHV+/EBV+; wt p53 
ATCC I, III, 
IV 
BC-3 Human primary effusion lymphoma cell line 
(PEL); KSHV+/EBV—; wt p53 
Dr. Ethel Cesarman I, II, 
III, IV 
BC-3/NF-kB luc Human primary effusion lymphoma cell line 
(PEL) carrying an NF-κB-regulated luciferase 
reporter gene; KSHV+/EBV—; wt p53 
Dr. Ethel Cesarman 
 
II 
BCBL-1 Human primary effusion lymphoma cell line 
heterozygous for the M246I mutation in one of 
the copies of the TP53 gene (PEL); 
KSHV+/EBV— 
Dr. Ethel Cesarman 
 
I, III, 
IV 
CZE Lymphoblastoid cell line (LCL); KSHV—/EBV+; 
wt p53 
This study I, II 
DG-75 Burkitt lymphoma cell line; KSHV—/EBV—; 
mutant p53 
ATCC I, II 
EA.hy926 Endothelial cell line derived from fusing human 
umbilical vein endothelial cells with the human 
lung carcinoma cell line A594; KSHV-/EBV-; wt 
p53 
Prof. Kari Alitalo 
(Edgell et al., 
1983) 
I, IV 
HL-60 Human promyelocytic leukemia cell line; KSHV—
/EBV—; p53 null 
ATCC I 
IHE Lymphoblastoid cell line (LCL); KSHV—/EBV+; 
wt p53 
This study I, II, 
IV 
IHH Lymphoblastoid cell line (LCL); KSHV+/EBV—; 
wt p53 
This study I, IV 
JOK-1 Human hairy-cell leukemia cell line; KSHV—
/EBV—; mutant p53 
Dr. Leif Andersson III 
JSC-1 Human primary effusion lymphoma cell line 
(PEL); KSHV+/EBV+; wt p53 
ATCC II, III, 
IV 
SLK Human endothelial cell line originally established 
from a mucosal Kaposi’s sarcoma lesion of an 
HIV-negative kidney transplant patient; KSHV—
/EBV— ; mutant p53 (D. Dittmer, personal 
communication) 
Prof. T. Schulz 
(Herndier et al., 
1994) 
IV 
U2OS Human osteosarcoma cell line; KSHV—/EBV—; 
wt p53 
ATCC I, II, 
III, IV 
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Table 3. Mouse lines used in this study 
Mouse line     Description Source or reference 
Used  
in 
BALB/c Nude 
Mouse 
Immunodeficient athymic nude mice Taconic I 
SCID Severe combined immunodeficient mice  
lacking both T and B lymphocytes 
Taconic II 
NOD/SCID Non-obese diabetic SCID mice  Taconic II 
 
Table 4. Expression vectors used in this study 
Vector     Description Source or reference 
Used  
in 
Lentiviral vectors 
pLKO.1-shNPM targets human NPM Open Biosystem IV 
pDSL_hpUGIH 
shCDK4 
targets human CDK4 (Koopal et al., 
2007) 
IV 
pDSL_hpUGIH 
shCDK6 
targets human CDK6 (Koopal et al., 
2007) 
IV 
pLenti6/V5-DEST-
GFP 
Encodes GFP Dr. Juergen Haas II, IV 
pLenti6/V5-DEST-
LANA 
Encodes LANA Dr. Juergen Haas II, IV 
Retroviral vectors 
v-FLIP-pBMN Encodes v-FLIP Dr. Johanna 
Furuhjelm 
IV 
v-cyclin-pBMN 
(KpBMN) 
Encodes v-cyclin Dr. Emmy 
Verschuren 
IV 
pSUPER.retro 
sh-v-cyclin 
Targets v-cyclin Dr. Rene Medema 
(Koopal et al., 
2007) 
IV 
Mammalian expression vectors 
Myc-v-cyclin/ 
pcDNA3 
Encodes myc-tagged v-cyclin Dr. Sibylle 
Mittnacht 
III 
Myc-p27/ 
pcDNA3 
Encodes myc-tagged human p27KIP1 Dr. Sibylle 
Mittnacht 
III 
Myc-p27S10A/ 
pcDNA3 
Encodes myc-tagged human p27KIP1 with  
a Ser-to-Ala point mutation S10A 
Dr. Sibylle 
Mittnacht 
III 
pEGFP-C1-B23.1 Encodes EGFP-tagged human NPM Dr. Kyosuke 
Nagata 
IV 
pEGFP-C1-B23.1-
T214/234/237A 
Encodes EGFP-tagged human NPM with  
Thr-to-Ala point mutations of codons 214, 234, 
and 233 (T3A) 
Dr. Kyosuke 
Nagata 
IV 
pEGFP-C1-B23.1-
T199/214/234/237A 
Encodes EGFP-tagged human NPM with  
Thr-to-Ala point mutations of codons 199, 214, 
234, and 233 (T4A) 
Dr. Kyosuke 
Nagata 
IV 
 
 MATERIALS AND METHODS  
                - 48 - 
Table 5. Primary antibodies used in this study 
Antibody      Description Source or reference 
Used  
in 
53BP1 Rabbit polyclonal antibody against 53BP1 Novus Biologicals I 
Acetyl-lysine (06-
933) 
Rabbit polyclonal antibody against acetyl-lysine Upstate 
Biotechnology 
IV 
Actin (C-2) Mouse monoclonal antibody against actin Santa Cruz 
Biotechnology 
I, II, 
III, IV 
Active caspase-3 Rabbit polyclonal antibody against cleaved 
caspase-3 
Cell Signaling 
Technology 
II 
Bax (B-9) Mouse monoclonal antibody against Bax Santa Cruz 
Biotechnology 
I 
BrdU (Bu20a) Mouse monoclonal antibody against BrdU DakoCytomation I 
CDK2 (M2) Rabbit polyclonal antibody against CDK2 Santa Cruz 
Biotechnology 
III 
CDK4 (DCS-35) Mouse monoclonal antibody against CDK4 NeoMarkers III 
CDK4 (H-22) Rabbit polyclonal antibody against CDK4 Santa Cruz 
Biotechnology 
IV 
CDK6 (Ab-3) Mouse monoclonal antibody against CDK6 NeoMarkers III 
CDK6 (C-21) Rabbit polyclonal antibody against CDK6 Santa Cruz 
Biotechnology 
III, IV 
Chk2 (DCS-270) Mouse monoclonal antibody against Chk2  Cell Signaling 
Technology 
I 
Cyclin A (C-19) Rabbit polyclonal antibody against cyclin A Santa Cruz 
Biotechnology 
IV 
Fibrillarin 
(ab5821) 
Rabbit polyclonal antibody against fibrillarin Abcam IV 
GFP (TP401) Rabbit polyclonal antibody against GFP Torrey Pines 
Biolabs 
IV 
HDAC1 (06-720) Rabbit polyclonal antibody against HDAC1 Upstate 
Biotechnology 
IV 
K8.1 A/B Mouse monoclonal antibody against K8.1 ABI 
Biotechnologies 
IV 
LANA Rabbit polyclonal antibody against LANA (Sharma-Walia et 
al., 2010) 
IV 
LANA (HHV8-
ORF73) 
Rat monoclonal antibody against LANA  ABI 
Biotechnologies 
I, II, 
IV 
MDM2 (2A10) Mouse monoclonal antibody against MDM2 Santa Cruz 
Biotechnology 
I, II 
MDM2 (IF-2) Mouse monoclonal antibody against MDM2 Oncogene Sciences I, II 
MDM2 (SMP14) Mouse monoclonal antibody against MDM2 Santa Cruz 
Biotechnology 
I, II 
Myc (9E10) Mouse monoclonal antibody against Myc-epitope Babco III, IV 
NPM (32-5200) Mouse monoclonal antibody against NPM Zymed IV 
ORF59 Mouse monoclonal antibody against ORF59 (Chan et al., 1998) II, III, 
IV 
p21 (C-19G) Rabbit polyclonal antibody against p21CIP1 Santa Cruz 
Biotechnology 
II 
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p21 (SX118) Mouse monoclonal antibody against p21CIP1 BD Biosciences-
Pharmingen 
I 
p27 KIP1 Mouse monoclonal antibody against p27KIP1 Upstate 
Biotechnology 
III 
p27KIP1 (C-19) Rabbit polyclonal antibody against p27KIP1 Santa Cruz 
Biotechnology 
III 
p300 (C-20) Rabbit polyclonal antibody against p300 Santa Cruz 
Biotechnology 
IV 
p53 (DO-1) Mouse monoclonal antibody against p53 Santa Cruz 
Biotechnology 
I, II 
p53 (FL-393) Rabbit polyclonal antibody against p53 Santa Cruz 
Biotechnology 
I, II 
p-Chk2 (Thr68) Rabbit polyclonal antibody against 
phosphorylated Chk2 (Thr68) 
Cell Signaling 
Technology 
I 
p-H2AX (Ser139) 
(JBW301) 
Mouse monoclonal antibody against the 
phosphorylated form of histone H2AX (Ser139) 
Upstate 
Biotechnology 
I 
Pim-1 (12H8) Mouse monoclonal antibody against Pim-1 Santa Cruz 
Biotechnology 
IV 
p-NPM (Thr199) Rabbit polyclonal antibody against 
phosphorylated NPM (Thr199) 
Cell Signaling 
Technology 
IV 
p-p27 (Ser10) Rabbit polyclonal antibody against 
phosphorylated  p27KIP1 (Ser10) 
Santa Cruz 
Biotechnology 
III 
p-p27 (Thr187) Rabbit polyclonal antibody against 
phosphorylated p27KIP1 (Thr187) 
Zymed III 
p-p53 (Ser15) Rabbit polyclonal antibody against 
phosphorylated p53 (Ser15) 
Cell Signaling 
Technology 
I 
Sp1 (PEP-2) Rabbit polyclonal antibody against Sp1 Santa Cruz 
Biotechnology 
III 
Tubulin (5H1) Mouse monoclonal antibody against tubulin BD Biosciences-
Pharmingen 
II, IV 
v-cyclin Rabbit polyclonal antibody against v-cyclin This study III, IV 
vIL-6  Rabbit polyclonal antibody against vIL-6 ABI 
Biotechnologies 
II, IV 
vIRF-3 (CM-
A807) 
Mouse monoclonal antibody against vIRF-3 Novus Biologicals IV 
β-tubulin (D-10) Mouse monoclonal antibody against β-tubulin Santa Cruz 
Biotechnology 
III 
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 Table 6. Methods used in this study 
Methods Used  in 
Bioluminescence imaging II 
BrdU incorporation assay I 
Cytocentrifugation  I, II,  
III, IV 
Flow cytometry I, IV 
Gel filtration chromatography I, III, 
IV 
Gene knockdown by RNA interference IV 
Immunofluorescence microscopy I, II,  
III, IV 
Immunohistochemistry IV 
Immunoprecipitation I, III, 
IV 
Implantation of tumor cells into mice I, II 
In vitro kinase assay  III, IV 
Lenti- and retroviral production IV 
Mammalian cell culture I, II,  
III, IV 
Measurement of apoptosis by Annexin V/PI I 
Production of anti-v-cyclin antibody III 
Production of infectious KSHV virions IV 
Quantitative real-time PCR II, IV 
Recombinant KSHV (rKSHV.219) production  I, IV 
Recombinant protein production in bacteria III 
RNA extraction II, IV 
SDS-PAGE and immunoblotting I, II,  
III, IV 
Statistical methods I, II,  
III, IV 
Subcellular fractionation III 
Transduction of mammalian cells I, IV 
Transfection of cells III, IV 
Ultracentrifugation IV 
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Cell culture, virus reactivation and drug treatments  
PEL cell lines, KSHV-negative LCL cells, JOK-1, DG-75, and HL-60 were cultured in 
a humidified 5% CO2 atmosphere at 37°C in RPMI 1640 medium supplemented with 
15% FCS (Invitrogen), 100 U/ml penicillin G, and 100 μg/ml streptomycin. U2OS 
human osteosarcoma, EA.hy926, and SLK endothelial cells were grown in DMEM 
supplemented with 10% FCS, 100 U/ml penicillin G, and 100 μg/ml streptomycin. To 
induce KSHV lytic replication, cells were treated with 20 ng/ml TPA (Sigma) or 1 mM 
NaB (Sigma). Inhibition of lytic gene expression was carried out with 5 µM of 
ganciclovir (Sigma). Inhibition of proteasome activity was performed with MG132. 
Treatment of PEL cells with MG132 in hypoxia or normoxia was first titrated to non-
toxic doses of 1 μM (data not shown). Hypoxia studies were performed by incubating 
cells in a 37°C incubator containing 1% O2 and 5% CO2 (INVIVO 400 Workstation; 
Ruskinn Technology Ltd, UK). The oxygen level was regulated by infusing nitrogen 
into a chamber controlled by a Gas Mixer Q controller (Ruskinn Technology Ltd).  
 
PEL cells, EBV-transformed LCL cells, and KSHV-infected LCL cells, suspended at  
2 × 105 cells/ml, were incubated with 7 μM Nutlin-3 (Cayman) or a comparable 
amount of the solvent (vehicle; 0.1% DMSO) for the indicated time. rKSHV-infected 
and non-infected parental U2OS and EA.hy 926 cells or U2OS cells stably expressing 
GFP or LANA were plated at a density of 0.5 × 105 cells per well in 24-well plates, 
and after 48 hours the cells were treated with 7 μM Nutlin-3. Cell viability was 
determined by trypan blue exclusion (Sigma-Aldrich). The control treatment with 
DMSO was always included, and the relative survival in each assay was calculated as 
the percentage of live cells relative to the live cell population in the control. To inhibit 
the ATM-Chk2 pathway in the KSHV-infected PEL cell line BC-1, KSHV-infected 
LCL IHH, or EBV-transformed LCL IHE, the cells were pretreated with 2 mM 
caffeine (Sigma-Aldrich) for 24 hours before the Nutlin-3 treatment. Caffeine was kept 
constant during exposure to Nutlin-3. 
 
Production of anti-v-cyclin antibody 
In order to produce recombinant v-cyclin fusion protein (GST-v-cyclin), the pCool 
vector (a modified version of pGEX-2T from Amersham Pharmacia Biotech) was 
expressed in Escherichia coli (Kaldis et al., 2001). The fusion protein was then bound 
to glutathione 4B sepharose beads. The beads were washed twice with cold phosphate-
buffered saline (PBS) to remove protease inhibitors, followed by incubation with 
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thrombin to remove the GST (1 mM CaCl2; 50 mM Tris, pH 8.0; 5 U/ml thrombin; 
Sigma, Steinheim, Germany) for 18 hours at 14°C. Rabbit polyclonal immunoglobulin 
G (IgG) antibodies directed against the thrombin-cleaved recombinant v-cyclin were 
produced by BIOTREND Chemikalien (Köln, Germany).  
 
Gel filtration chromatography 
Cell lysates prepared in ELB (150 mM NaCl; 50 mM HEPES, pH 7.4; 0.1% Igepal;  
5 mM EDTA; 2 mM DTT) or NET (50 mM Tris-HCl, pH 7.5; 0.2% Ipegal; 1 mM 
EDTA; 150 mM NaCl) lysis buffers in the presence of phosphatase inhibitor cocktail 
tablets (PhosphoSTOP, Roche) and protease inhibitors (Complete tablets, Roche) were 
passed through a 0.22-µm pore size MILLEX-GS filter (Millipore) and fractionated on 
a Superdex 200 HR column by a fast protein liquid chromatography (FPLC) system 
(Pharmacia Biotech). Samples were loaded onto the column and separated in a gel 
filtration buffer (50 mM HEPES, pH 7.5; 150 mM NaCl) at a flow rate of 0.3 ml/min. 
The molecular mass standards (Sigma) used to calibrate the column were blue dextran 
(2000 kDa), thyroglobulin (669 kDa), apoferritin (443 kDa), β-amylase (200 kDa), 
alcohol dehydrogenase (150 kDa), bovine serum albumin (BSA; 66 kDa), and carbonic 
anhydrase (29 kDa). For each fractionation, 30 fractions of 0.5 ml were collected. Fifty 
microliters of each fraction served for immunoblotting and 450 µl of each fraction for 
immunoprecipitation experiments.  
 
In vitro kinase assay 
Whole-cell extracts from PEL cells or fractions from gel filtration chromatography 
were incubated for 2 hours at 4°C with the rabbit polyclonal anti-v-cyclin antibody. 
Immunocomplexes were coupled to protein A sepharose beads for an additional  
2 hours at 4°C and washed three times with the lysis buffer followed by two washes 
with the kinase buffer (20 mM Tris, pH 7.5; 50 mM KCl; 7.5 mM MgCl2; 10 mM 
MnCl2 1 mM DTT; 25 mM β-glycerophosphate; 2 µg/ml leupeptin; 2 µg/ml pepstatin;  
and 1.5 µg/ml aprotinin). Kinase reactions were performed by incubating the 
immunocomplexes with 10 µl kinase buffer containing 2 µCi (0.074 MBq) [32P] 
adenosine triphosphate (ATP) for 20 minutes at 30°C. The in vitro kinase activity was 
measured toward v-cyclin coimmunoprecipitated proteins or Histone H1  
(Roche Diagnostics), GST-pRb, or GST-p27KIP1. To this end, 2 µg Histone H1  
and GST-pRb or 0.5 µg GST-p27KIP1 were added to the kinase reactions as 
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substrates. Reactions were terminated by the addition of 5 × SDS-PAGE sample 
buffer, were resolved in SDS-PAGE, and analyzed by autoradiography. The extent of 
[32P] incorporation into the substrates was quantified from the autoradiographs by the 
Typhoon 9400 Image Quant analyzer (Amersham Biosciences).  
 
Establishment of EBV-transformed and KSHV-infected LCL cells 
PBMCs were isolated from EDTA-treated blood of two healthy individuals by 
discontinuous gradient centrifugation (Lymphoflot; Biotest). To induce the expression 
of lytic viral proteins in EBV-positive B95-8 or KSHV-positive BCBL-1 cells, cells 
were treated with either TPA (Sigma-Aldrich) or 3 mM NaB (Sigma-Aldrich) for 24 
hours. Supernatants of the B95-8 or BCBL-1 cells grown at densities greater than  
5 × 105/ml were filtered through 0.4-μm filters and serially diluted in flat-bottomed  
96-well microtiter plates. Subsequently, PBMCs were added at a density of 104 cells 
per well. The culture medium used to generate LCL cells contained RPMI, 20% heat-
inactivated FCS, 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine,  
1 mM sodium pyruvate (Invitrogen), 20 mM bathocuproine disulfonic acid,  
and 50 μm/ml α-thioglycerol (Sigma-Aldrich). 
 
rKSHV.219 production and infection of target cells  
Vero cells latently infected with a GFP-expressing rKSHV (rKSHV.219), were used to 
produce infectious virus as described (Vieira and O'Hearn, 2004). In brief, 80% to 
90% confluent rKSHV.219 Vero cells in six-well plates were reactivated by adding 
400 μl/well of a recombinant baculovirus (BacK50) expressing the KSHV lytic 
activator ORF 50 (RTA; a gift from J. Vieira) for 2 hours, removed, and replaced with 
complete media (DMEM:RPMI; 40:60) containing 1.25 mM sodium butyrate  
(Sigma-Aldrich). Supernatants containing rKSHV.219 were collected 72 hours later. 
U2OS, EA.hy926, and SLK cells were plated at a density of 2 × 105 cells per well in  
a six-well dish and were infected the next day with 1.0 ml/well of rKSHV.219 virus 
supernatant in the presence of 8 μg/ml polybrene to enhance their infectivity. The 
plates were spin-transduced by centrifugation at 1,050 g (Heraeus Multifuge) for  
30 minutes at RT. Cells were returned to 37°C at 5% CO2 for 2 hours, after which the 
rKSHV.219 supernatant was replaced with complete DMEM media. Cells were 
routinely cultured in a humidified 5% CO2 atmosphere at 37°C in DMEM containing 
10% (w/v) FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin in the presence of  
1 μg/ml puromycin, which was included 2 days after infection. Infected cells were 
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grown in the presence of puromycin for about one week to obtain a 100% infected 
stable cell line.  
 
Lenti- and retroviral production and transduction 
Production of retro- and lentiviruses and CDK silencing in EA.hy926 and SLK cells 
were performed as described (Koopal et al., 2007). Briefly, lentiviral supernatants 
were generated by transfection of Invitrogen ViraPowerTM viral packaging plasmids 
pLP1, pLP2, and pLP/VSVG, together with the lentiviral expression plasmid into 
293FT cells (ATCC) by use of the LipofectamineTM 2000 reagent (Invitrogen). 
Transfections were performed with 4 x 106 293FT cells per 10-cm cell culture dish 
(Reverse transfection procedure, Invitrogen). Packaging plasmids  
(pLP1 : pLP2 : pLP-VSVG) were used in the ratio of 1 : 0.47 : 0.65 (2.83µg : 1.33µg : 
1.84µg). Amphotropic retroviruses were produced by transfection of Phoenix-Ampho 
retrovirus–producing cells with retroviral vectors by use of Lipofectamine 2000 
reagent. Viral supernatants were harvested 72 hours after transfection through sterile 
0.22-μm-pore-size filters (Millipore), aliquoted, and stored at -80°C until further use. 
To silence the CDKs and NPM, the PEL cells were seeded at density 5 × 105/ml and 
transduced in a 50-ml culture flask with 2 ml lentiviral supernatants in the presence of 
8 µg/ml polybrene (Sigma); 24 hours after transduction, the culture was replenished 
with fresh media, and cells were kept for 48 hours, after which they were subjected to 
selection with 3.5 µg/ml puromycin (silencing of NPM) or 300 µg/ml hygromycin 
(silencing of CDKs). 
For an acute depletion of v-cyclin expression in the rKSHV.219-SLK cells, the cells 
were spin-transduced (2500 rpm; Heraeus Multifuge) for 30 min at RT with fresh 
amphotropic retroviruses expressing control sh-RNA (sh-Scr) or sh-RNA against  
v-cyclin (sh-v-cyclin) in the presence of 8 µg/ml polybrene. Cells were then returned 
to 37°C in 5% CO2, and after 24 hours of incubation, the viral supernatant was 
removed and replaced with fresh complete media. Cells were harvested for analysis 48 
hours post-transduction. 
U2OS osteosarcoma cells were spin-transduced as described above with GFP- or 
LANA-expressing lentiviruses in the presence of 8 µg/ml polybrene, and the cells were 
incubated for 48 hours. Thereafter, LANA and GFP-expressing cells were cultured in 
the presence of 5 µg/ml of blasticidin (Sigma) for at least two weeks. Stable expression 
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of the transduced proteins was assessed by immunofluorescence and Western blotting 
using anti-GFP or anti-LANA antibodies. 
 
Measurement of cell proliferation and detection of apoptosis 
The proportion of cells at the S phase was determined by measuring incorporation of 
BrdU and PI into the DNA. Cells were grown at a density of 2 × 105 cells/ml 24 hours 
prior to the treatment with Nutlin-3. The cells were pulse-labeled with 25 μM BrdU 
(Sigma-Aldrich) for 30 minutes and fixed in ice-cold 70% ethanol. After fixation, the 
cells were washed in PBS and treated with 3.5 N HCl for 30 minutes at room 
temperature. After being washed in a neutralizing washing buffer (0.1% BSA/PBS), 
the cells were incubated with an anti-BrdU antibody (Dako; 1:50) for 45 minutes. 
Alexa Fluor 488-conjugated (Invitrogen) secondary antibody served for detection. 
Finally, the cells were stained with 30 μg/ml PI (Invitrogen) in PBS supplemented with  
50 μg/ml RNase (Sigma-Aldrich) for 30 minutes at 37°C. Apoptosis was measured by 
dual-labeling with the Annexin V-FITC Apoptosis Detection kit I (Pharmingen) 
according to manufacturer’s instructions and analyzed by flow cytometry. Labeled 
cells were acquired by a BD-LSR Flow Cytometer (BD Biosciences), and the cell 
populations were analyzed by CellQuest software (BD Biosciences).  
 
Apoptotic cells were detected by an in situ cell death detection kit (TMR red; 
Roche Applied Science), according to manufacturer's instructions. This assay measures 
DNA fragmentation by immunofluorescence using TUNEL (terminal deoxynucleotidyl 
transferase-mediated dUTP nick end-labeling) method at the single-cell level. Per 
sample, 500 cells were counted to quantitate the percentage of apoptotic PEL cells. 
 
In vivo studies  
Female Balb/c nude mice (4 to 6 weeks old, Taconic) were maintained under specific 
pathogen-free conditions in a temperature- and humidity-controlled environment. Mice 
under anesthesia were injected subcutaneously with 6 × 106 BC-3 cells in  
50% Matrigel (BD Biosciences). Treatment was started intraperitoneally after the 
tumors were established (i.e., palpable). Nutlin-3 (20 mg/kg) or the vehicle control was 
administered every second day for a total of 2 weeks (7 doses). Tumor volumes were 
measured with a caliper and calculated according to the formula V = width × height × 
depth/2, derived from the formula for the volume of an ellipsoid. In order to monitor 
the health of the animals, the mice were weighed once a week.  
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Intraperitoneal PEL tumors using BC-3/NF-κB-luc cells in female SCID and 
NOD/SCID mice (Taconic Europe) were established as previously described 
(Keller et al., 2006). To monitor tumor growth, D-luciferin (SYNCHEM OHG, 
Germany) in PBS (100 mg/kg) was injected i.p., and mice were imaged by the IVIS 
Imaging system (Xenogen). Data were analyzed with The Living Image software 
(Xenogen). For quantitative analysis, a constant region-of-interest (ROI) was drawn 
over the tumor region, and the intensity of the signal was measured as total 
photon/s/cm2/steradian (p/s/cm2/sr). Every second day, 20 to 40 mg/kg Nutlin-3 
(Cayman Chemical, MI) or the vehicle control (DMSO) were administered 
intraperitoneally.  
 
DNA isolation and quantitative genome copy-number analysis 
Prior to DNA extraction, rKSHV-EA.hy926 and -SLK cells were washed with PBS 
and stored at −70°C as a dry pellet of 2 × 106 cells. DNA was extracted according to 
standard protocol by proteinase K digestion and isopropanol precipitation. Briefly, the 
cell pellet was resuspended in 300 µl of lysis buffer (200 mM NaCl; 40 mM Tris-HCl, 
pH 8.0; 20 mM EDTA; 0.5% sodium dodecyl sulphate; 0.5% β-mercaptoethanol;  
1 mg of proteinase K per ml) and incubated 10 min at RT. The cell lysate was 
subjected to DNA extraction with isopropanol, and DNA was precipitated by 
centrifugation (13,300 g for 15 min). DNA was then washed twice with 70% ethanol, 
dried, and resuspended in 100 µl of TE buffer. Quantitative real-time PCR with LANA 
primers to measure the copies of KSHV genomes was performed as detailed 
previously (Lallemand et al., 2000; Cai et al., 2005). 
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RESULTS AND DISCUSSION 
 
1. Restoration of p53 function by MDM2 inhibition as a novel 
therapeutic modality against PEL cells (I) 
1.1 Inhibition of MDM2 leads to cell cycle arrest and apoptosis in PEL cells  
There exists currently no optimal therapy for PEL, and new therapeutic approaches for 
PEL with potential clinical applicability are urgently needed. Alterations in the p53 
gene (TP53) in KSHV-associated malignancies are very rare (Nador et al., 1996; 
Carbone et al., 1998; Katano et al., 2001b; Chadburn et al., 2004). Since the p53 
pathway in PEL cells is functional in response to a common cytotoxic drug, 
doxorubicin (Petre et al., 2007), we investigated the outcome of non-genotoxic 
activation of the p53 pathway by the small-molecule inhibitor Nutlin-3 (I).  
 
First, we performed experiments using a panel of patient-derived, naturally KSHV-
infected PEL cell lines: BC-1, BC-3, and BCBL-1. Asynchronously growing PEL cells 
were treated with 7 µM Nutlin-3 for 12 hours. Whole-cell lysates were subjected to 
SDS-PAGE, followed by immunoblotting with anti-p53 antibody. The analysis 
revealed rapid accumulation of p53 in BC-1 and BC-3 cells (Fig. 1 in I). However, the 
BCBL-1 cell line, shown to be heterozygous for the M246I mutation in one of the 
copies of the TP53 gene (Katano et al., 2001b; Petre et al., 2007), displayed a delayed 
induction of p53 (Fig. 1 in I). Subsequently, the samples were analyzed for the 
induction of p53 targets that mediate cell cycle arrest and apoptosis. The 
immunoblotting analysis, using antibodies against p21CIP1 and Bax, revealed a robust 
induction of both targets in BC-1 and BC-3 cell lines (Fig. 1 in I).  
 
Secondly, we assessed the effect of Nutlin-3 on cell cycle progression. BC-1, BC-3, 
and BCBL-1 cells exposed to Nutlin-3 for 12, 24, or 48 hours were labeled with 
bromodeoxyuridine (BrdU) and propidium iodide (PI), and analyzed by flow 
cytometry (Fig. 2A in I). Typically, within 12 to 24 hours of Nutlin-3 treatment, we 
observed a strong G1 arrest and a dramatic decrease in the accumulation of all PEL 
cells in the S phase (Fig. 2A in I). Interestingly, prolonged exposure to Nutlin-3 
resulted in a further increase in the cells at G1, and an increase in the number of cells 
in the sub-G1 phase, suggesting elevated levels of cell death (Fig. 2A in I). We thus 
aimed to determine whether the sub-G1 phase cells were apoptotic. To this end, we 
treated BC-1 cells with 7 µM Nutlin-3 for up 120 hours, whereas BC-3 and BCBL-1 
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cells were incubated with the same Nutlin-3 dose for 96 hours. Subsequently, cells 
were stained with Annexin V/PI and subjected to flow cytometric analysis. We found a 
massive apoptosis in all PEL cell lines tested (Fig. 3B-C in I). Interestingly, the 
pronounced apoptosis observed in BC-1 cells between 48 and 72 hrs (Fig. 3B in I) 
overlaps the time course of Bax expression upon Nutlin-3 treatment in this cell line, as 
we have shown in a later report (Sarek and Ojala, 2007), supporting the importance of 
Bax in p53-mediated apoptosis in PEL cells. Following the Nutlin-3 treatment, at all 
time-points analyzed (6 to 72 hours), we further revealed high expression of p21CIP1 
in BC-1 cells. Collectively, this shows that PEL cells have a functional p53, and that 
restoration of its activity by MDM2 inhibition results in massive apoptosis. 
 
It has been suggested that the cell cycle arrest mediated by induction of p21CIP1 may 
be an early event in the cascade by which activation of p53 leads to apoptosis 
(Meikrantz and Schlegel, 1995; Kang et al., 1999; Poole et al., 2004). On the other 
hand, high expression of p21CIP1 may protect cells against apoptosis (Suzuki et al., 
1998; Asada et al., 1999), and act as a critical determinant for the non-apoptotic 
cellular response to Nutlin-3 observed in colon cancers (Donner et al., 2010). An 
interesting recent study by Enge and coworkers (2009) has revealed that the p53-
reactivating compound RITA releases MDM2 from p53, and this promotes 
degradation of both p21CIP1 and the transcriptional cofactor hnRNP K required for 
p53-mediated induction of the CDKN1 gene. As a consequence, that p21CIP1 was 
unable to execute its growth-suppressive function favored p53-dependent apoptosis in 
the HCT-116 colon carcinoma cell line (Enge et al., 2009). In contrast, treatment with 
Nutlin-3 induced binding of hnRNP K to the upstream site of the CDKN1A promoter, 
leading instead of to apoptosis, to p21CIP1 induction and cell-cycle arrest (Enge et al., 
2009). Therefore, regulation of p21CIP1 expression may represent a major switch 
between growth arrest and apoptotic response to p53 restoration. We have however, 
observed a massive apoptotic response to Nutlin-3 in the PEL cells (I), despite high 
p21CIP1 induction (Sarek and Ojala, 2007).  If p21CIP1 represents the major 
determinant of the non-apoptotic response, how can this apparent discrepancy be 
explained? As v-cyclin inhibits the cell cycle-arresting activity of p21CIP1 by 
phosphorylation on Ser130 (Swanton et al., 1997; Jarviluoma et al., 2006), it is 
possible that v-cyclin is at least partially involved in directing the response towards 
apoptosis. However, this theory requires further experimentation. 
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1.2 Restoration of the p53 pathway selectively kills KSHV-infected cells 
To assess whether restoration of the p53 pathway by Nutlin-3 selectively targets 
KSHV-infected lymphoblastoid cells for apoptosis, we examined the response to 
Nutlin-3 treatment in two KSHV-negative, EBV-immortalized lymphoblastoid cell 
lines (LCL; CZE and IHE) which express wt p53 (I). CZE and IHE were treated with 7 
µM Nutlin-3 for 12 hours and analyzed by immunoblotting using anti-p53 and anti-
p21CIP1 antibodies. Similar to PEL cells (see 1.1 and Fig. 1 in I), the KSHV-negative 
LCL cells displayed a strong induction of p53 and its target p21CIP1 (Fig. 1 in I). 
Next, we examined whether KSHV-negative LCL cells undergo cell cycle arrest in 
response to Nutlin-3 treatment. CZE and IHE cells were exposed to Nutlin-3 for 24 
and 48 hours, labeled with BrdU and PI, and analyzed by flow cytometry. The results 
revealed that LCL cells, similar to PEL cells (see 1.1 and Fig. 2A in I), can undergo an 
efficient G1 arrest in response to Nutlin-3 (Fig. 2B in I).  
 
Next, we assessed the cytotoxicity of Nutlin-3 in three PEL cell lines (BC-1, BC-3, 
and BCBL-1), in the KSHV-infected lymphoblastoid cell line IHH, and in KSHV-
negative LCL cells (CZE and IHE). To this end, all cells were treated with 7 µM 
Nutlin-3 for 5 days, and their viability was determined by trypan blue exclusion. We 
observed a 60% to 90% reduction in survival of all KSHV-infected cells after 5 days 
of p53 restoration (Fig. 3A in I). However, during the treatment period, viability of the 
KSHV-negative LCL cells declined only minimally (Fig. 3A in I). To confirm the lack 
of apoptotic response in the KSHV-negative LCL cells upon Nutlin-3 treatment, we 
performed AnnexinV/PI flow cytometric analysis, analogous to that described above 
for PEL cells (see 1.1). In contrast to PEL cells (see 1.1 and Fig. 3B in I), the KSHV-
negative LCL cells did not undergo apoptosis (Fig. 3C in I). All together, these results 
suggest that restoration of p53 function selectively induces apoptosis in KSHV-
infected lymphoblastoid cells, but not in the KSHV-negative LCL cells. 
 
The notable increase in the p53-dependent apoptosis in both PEL cells and the KSHV-
positive lymphoblastoid cell line IHH over the KSHV-negative LCL cells (I) suggests 
that KSHV infection may somehow enhance cytotoxic effects upon Nutlin-3. To 
further examine this possibility, we used U2OS osteosarcoma and EA.hy926 
endothelial cells (Edgell et al., 1983) that have been remarkably resistant to Nutlin-3-
induced apoptosis (Tovar et al., 2006; Shen et al., 2008). We de novo infected these 
cell lines with recombinant KSHV (rKSHV.219; (Vieira and O'Hearn, 2004), and 
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subsequently treated them with 7 µM Nutlin-3 for 24, 48, and 96 hours (I). Parental 
non-infected U2OS and EA.hy926 served as a control, and the cytotoxic effect of 
Nutlin-3 was determined by trypan blue exclusion. Following 96 hours of Nutlin-3 
treatment, we observed about a four-fold increase in cell death in KSHV-infected 
U2OS and EA.hy926 cells when compared to their non-infected parental cells (Fig. 4A 
in I). A similar observation was reported also in regards to human dermal 
microvascular endothelial cells (Koopal et al., 2007). Collectively, these data 
confirmed that MDM2 inhibition induced cytotoxic activity selectively in KSHV-
infected cells.  
 
1.2.1 Active DNA-damage signaling in PEL cells augments cytotoxicity of Nutlin-3  
The selective cytotoxicity of Nutlin-3 towards KSHV-infected cells prompted us to 
examine the underlying mechanisms. Stimulated by discovery of a recently described 
property of cancer cells to activate DNA damage signaling (Bartkova et al., 2005; 
Gorgoulis et al., 2005), and the role of 53BP1 in promoting the cellular cytotoxicity of 
Nutlin-3 (Brummelkamp et al., 2006), we evaluated whether the DNA damage 
response could contribute to the selectivity of Nutlin-3 in PEL cells (I). Cellular DNA 
damage is marked by the presence of nuclear foci, which contain phosphorylated 
histone H2AX (γH2AX) and 53BP1 (Rogakou et al., 1998; Chehab et al., 2000; 
DiTullio et al., 2002; Gorgoulis et al., 2005). To explore activation of the DNA 
damage signaling in PEL cells we performed immunostaining with an antibody against 
γH2AX, and quantified the γH2AX foci in BC-1, BC-3, and BCBL-1, and in the 
KSHV-negative LCL cells (CZE and IHE) (Fig. 5A-B in I). We found that 50% to 
70% of PEL cells showed accumulation of the DNA damage response signal, whereas 
only 20% of the control LCL cells were affected (Fig. 5A-B in I). Notably, the lower 
number of foci in the control LCL cells was not due to a defect in DNA damage 
detection or impaired signaling, because these cells remained fully capable of forming 
γH2AX foci in response to IR (data not shown in I).  
 
To investigate the involvement of DNA damage checkpoint activation in Nutlin-3-
mediated cytotoxicity, we pretreated KSHV-infected BC-1 and IHH cell lines with  
2 mM caffeine, an inhibitor of the ATM-Chk2 DNA damage pathway, for 24 hours, 
followed by Nutlin-3 treatment (Fig. 5D in I). We observed that the caffeine treatment 
greatly impaired the Nutlin-3-induced apoptosis in KSHV-infected cells (Fig. 5D in I). 
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This demonstrated that activated DNA damage signaling indeed contributes to the 
Nutlin-3-induced cell death in PEL cells.  
 
A synergistic effect between cytotoxic drugs and Nutlin-3 enhances apoptosis in 
multiple myeloma, in mantle cell lymphoma, and in a broad panel of leukemia cell 
lines (Kojima et al., 2005; Stuhmer et al., 2005; Coll-Mulet et al., 2006; Secchiero et 
al., 2006; Tabe et al., 2009). This strongly supports our findings here that DNA 
damage signaling is essential for the Nutlin-3-induced cytotoxicity in PEL cells (I). 
Because v-cyclin induces strong DNA damage in human primary and immortalized 
dermal microvascular endothelial cells (Koopal et al., 2007), the activated DNA 
damage response observed in PEL cells (I) may result from the constitutive expression 
of v-cyclin.  
 
1.2.2 Disruption of the p53-MDM2-LANA complex sensitizes PEL cells to 
apoptosis upon p53 restoration 
As restoration of the p53 function with Nutlin-3 leads to inhibition of the p53-MDM2 
interaction and to consequent activation of the p53 signaling pathway (Vassilev, 2004; 
Vassilev et al., 2004; Vassilev, 2005), we investigated whether the major latency-
associated nuclear antigen LANA would form a complex with p53 and MDM2 (I).  
We focused on LANA, since it interacts with p53, inhibits p53-mediated apoptosis 
(Friborg et al., 1999), and represses the p53-driven transcription of the pro-apoptotic 
protein Bax (Wong et al., 2004).  
 
To examine whether LANA could form complexes with p53 and MDM2, we subjected 
BC-3 cell extracts to gel filtration chromatography followed by reciprocal 
immunoprecipitation with anti-p53 and anti-MDM2 antibodies (Fig. 6A-B in I). The 
immunocomplexes were resolved by SDS-PAGE and analyzed by Western blotting 
using antibodies against p53, MDM2, and LANA. Immunoblot analysis revealed 
LANA as a component of the p53-MDM2 complex in BC-3 cells (Fig. 6B in I).  
 
Next, we examined whether treatment of PEL cells with Nutlin-3 disrupts the p53-
MDM2-LANA ternary complex. To this end, BC-3 cells were treated with 7 µM 
Nutlin-3 for 12 hours. The cell lysates were fractionated by gel filtration 
chromatography and subjected to immunoprecipitation using anti-p53 and anti-MDM2 
antibodies. The resulting co-precipitates were analyzed by Western blotting using 
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antibodies directed against p53, MDM2, and LANA (Fig. 6B in I). We found that 
treatment of BC-3 cells with Nutlin-3 abolished the interaction of LANA with both 
p53 and MDM2 (Fig. 6B in I). Thus, the release of both p53 and MDM-2 from LANA 
may contribute to the specificity of Nutlin-3-induced apoptosis in PEL cells.  
 
Very recently, Chen and coworkers (2010) confirmed our findings by purifying LANA 
complexes from PEL cells. Moreover, the authors suggested that only a minor, 
phosphorylated fraction of LANA is able to bind to MDM2, and further speculated that 
MDM2 may either directly contribute to the p53-LANA interaction or may change the 
conformational state of p53 to allow its interaction with LANA (Chen et al., 2010). In 
the light of these findings, it would be of great importance to investigate whether 
MDM2 associates with LANA in a direct or in a p53-mediated manner.   
 
1.2.3 High levels of MDM2 and co-infection with EBV may sensitize PEL cells to 
Nutlin-3-induced cytotoxicity  
As demonstrated above, KSHV-infection, intrinsic DNA damage signaling, and 
disruption of the p53-MDM2-LANA complex may all contribute to Nutlin-3-induced 
cytotoxicity in PEL cells. We thus aimed to identify other potential factors able to 
influence the cytotoxicity mediated by Nutlin-3 (I). 
 
As elevated expression of MDM2 in cancer cells can promote selective cytotoxicity of 
Nutlin-3 (Patton et al., 2006; Tovar et al., 2006), we first wanted to examine whether 
MDM2 levels in PEL cells correlate with Nutlin-3-induced cytotoxicity. To this end, 
PEL cells (BC-1, BC-3, and BCBL-1) and KSHV-negative LCL cells (CZE and IHE) 
were lysed and subjected to immunoblotting with anti-MDM2 antibody (Fig. 1 in I). 
The results revealed markedly higher levels of MDM2 in PEL cells than in KSHV-
negative LCL cells (Fig. 1 in I). This is in line with previous findings demonstrating 
that among over 60 B-cell tumors only PEL display highly elevated MDM2 transcripts 
(Petre et al., 2007). 
 
Another factor that could theoretically sensitize cells to Nutlin-3-induced cytotoxicity 
is coinfection with EBV. Treatment of wt p53-bearing Burkitt’s lymphoma (BL) cells 
with Nutlin-3 restores their p53 pathway regardless of their EBV status (Renouf et al., 
2009). Apoptosis in response to Nutlin-3 occurs in BL cells expressing the EBV 
latency program I, whereas BL cells in EBV latency program III undergo strong cell 
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cycle arrest but no apoptosis (Renouf et al., 2009). Importantly, the majority of PEL 
cells, including the BC-1 cell line, are dually infected with KSHV and EBV (Cesarman 
et al., 1995a; Renne et al., 1996b; Carbone et al., 1998), which may influence their 
response to restoration of the p53 pathway. Dually infected PEL cells display the 
restricted EBV latency program I (Horenstein et al., 1997; Szekely et al., 1998), which 
is in accordance with our results demonstrating that the most efficient apoptotic 
response occured in the dually infected BC-1 cell line (Fig 3A-B in I). Furthermore, 
lymphoblastoid cells exhibit the type III latency program (Lewin et al., 1995; Szekely 
et al., 1998), supporting our finding that the type III latency LCL cells (CZE and IHE) 
underwent growth arrest without apoptosis (Fig. 2B in I). To conclude, EBV 
coinfection may predispose PEL cells to Nutlin-3-induced cell death.   
 
2. Restoration of the p53 pathway as a treatment for KSHV 
lymphomas in vivo (I, II) 
2.1 MDM2 inhibition by Nutlin-3 eradicates subcutaneous PEL tumors in mice 
Since our in vitro studies demonstrated the potential of restored p53 in specific PEL 
cell killing, we aimed to confirm this observation in vivo (I and II). We thus explored 
the effect of MDM2 inhibition by Nutlin-3 in a human subcutenaeous (s.c.) mouse 
model for PEL (I). Balb/c nude female mice were xenografted with 6 × 106 BC-3 cells 
in matrigel, and their tumors were allowed to grow until palpable. To treat these 
tumor-bearing mice, we administered Nutlin-3 by an i.p. route, at 20 mg/kg of body 
weight, every second day for the course of two weeks (I). Animals treated with Nutlin-
3 showed a dramatic regression in tumor growth, in contrast to mice receiving vehicle 
control (Fig. 7 in I). After three doses of Nutlin-3, we observed significant tumor 
shrinkage (Fig. 7 in I), and after seven doses, 40% of the mice showed complete tumor 
remission (I). We followed these mice for over 90 days and observed no tumor 
recurrence (I). However, after treatment cessation, those tumors that had displayed  
a delayed response to Nutlin-3 resumed proliferation. The size of these tumors did, 
however, remain smaller than in the control mice (I). Furthermore, additional Nutlin-3 
treatment of those tumors with partial responses led to their regression without signs of 
recurrence during the follow-up period (I). This suggests that p53 restoration by 
MDM2 antagonists may offer an effective treatment modality for KSHV-associated 
lymphomas (Fig. 5).  
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Figure 5. Restoration of p53 function by an MDM-2 antagonist as a therapeutic modality in 
primary effusion lymphomas.  In PEL cells, LANA binds p53 and MDM2, which represses the p53 
function and allows tumor development in mice. Treatment with Nutlin-3 releases p53 from the negative 
regulation of LANA. Inhibition of MDM2 binding to p53 leads to p53 stabilization, activation, and 
accumulation of transcriptionally active tetramers. The subsequent activation of the p53 pathway and 
p53-target genes induces cell cycle arrest and apoptosis, thus leading to tumor eradication. 
 
2.2 Anti-tumor activity of Nutlin-3 occurs in intraperitoneal PEL tumors in mice 
Investigation of biological processes such as tumor growth and response to specific 
therapies benefits from preclinical animal models in which quantitative and non-
invasive detection of tumor cells can be perfomed. As the results described above were 
based on s.c. PEL tumors in mice, we next chose an animal model to better recapitulate 
features of the human disease, and to allow more quantitative follow-up of the 
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treatment (II). To achieve this, we injected KSHV-positive BC-3 PEL cells (1 × 107) 
carrying an NF-κB-regulated luciferase reporter gene (BC-3/NF-κB-luc (Keller et al., 
2006)) into the body cavity of severely immuno-compromised NOD/SCID mice (II). 
We monitored tumor formation by whole-body imaging using the IVIS imaging 
system (II). We started the i.p. Nutlin-3 (40 mg/kg) administration every second day 
after tumor establishment (average luciferase signal intensity 1 × 105 to 4 × 105 
photons), for two weeks.  We evaluated tumor response to Nutlin-3 by in vivo 
bioluminescence imaging in real time in live animals (II). We observed that mice 
within a control group (n=12) that received vehicle (DMSO) showed a continuous 
increase in the bioluminescence signal associated with tumor growth (Fig. 2A-B in II). 
In contrast, 87% of Nutlin-3-treated mice (n = 15) showed a reduction in tumor mass. 
Within this group, after 14 days of treatment, 60% of the mice achieved total tumor 
regression (Fig. 2A-B in II). One mouse had a residual tumor despite Nutlin-3 
treatment and showed a weight gain six days after treatment cessation, indicating 
resumed cell proliferation (Fig. S2A in II). However, re-treatment with six doses of 
Nutlin-3 (20 mg/kg) for two weeks resulted in complete tumor eradication (Fig. S2B in 
II).  
 
Next, to examine the involvement of p53 activation in the Nutlin-3 response of the IP 
tumors (II), we collected tumors from ascites of Nutlin-3- or DMSO- treated mice 24 
hours after the fourth dose. When these tumor cells were examined by 
immunofluorescence using antibodies against p53 and the p53 target p21CIP1 (Fig. 
S2C in II), increased p53 and p21CIP1 signal was evident in Nutlin-3-treated tumors, 
whereas DMSO-treated tumors showed the basal level of p53 and no p21CIP1 
induction (Fig. S2C in II). Further examination by TUNEL assay of these tumor cells 
for apoptosis revealed nearly 20% of apoptotic cells in the Nutlin-3-treated tumor and 
only 2% in the DMSO-treated tumor (Fig. S2D in II). To conclude, p53 accumulation 
and induction of apoptosis upon Nutlin-3 treatment led to PEL tumor regression. 
 
Radiosensitive tissues such as small-intestine epithelium and thymus are extremely 
susceptible to p53-induced apoptosis (Lowe et al., 1993; Potten et al., 1997). 
Moreover, restoration of p53 function by a genetic approach in the absence of MDM2 
triggers massive apoptosis in radiosensitive mouse organs, followed by death of the 
animals within five days (Ringshausen et al., 2006). This prompted us to study 
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whether pharmacological activation of p53 will also be toxic to healthy tissues (II). To 
assess this in our system, we studied the effect of p53 restoration in radiosensitive 
(small intestine, spleen) and radioresistant (heart, lungs, kidney) organs of NOD/SCID 
mice treated with eight doses of Nutlin-3 (20 mg/kg) for two weeks (II). The organs 
were examined by TUNEL immunofluorescence assay, revealing that MDM2 
inhibition caused neither apoptosis nor atrophy (Fig. S3 in II). These results are also 
supported by others’ reports that Nutlin-3 is well tolerated by mice and that 
accumulation of p53 after MDM2 inhibition does not cause profound pathological 
changes in normal tissues (Vassilev et al., 2004; Tovar et al., 2006). 
 
Taken together, our data provide, to our knowledge, the first in vivo experimental 
evidence of p53 restoration in mice and demonstrate in the mouse models remarkable 
anti-tumor activity against KSHV lymphomas. This warrants further evaluation in 
preclinical and clinical studies and may provide new measures to treat aggressive 
KSHV lymphomas.  
 
2.3 The p53 pathway can be efficiently restored in clinical PEL tumors ex vivo 
Because an important prerequisite of the novel cancer therapeutic agents is their ability 
to inhibit the survival and growth of primary tumor cells isolated from humans, we 
tested whether the p53 pathway can be restored in primary tumors isolated from 
patients diagnosed with PEL (II). To this end, we used ascitic fluids containing large 
lymphomatous cells, with all their morphological features consistent with a PEL 
diagnosis, isolated from HIV-positive patients (II). Primary PEL tumors were treated 
ex vivo with 7 µM Nutlin-3 or vehicle control for 24 or 48 hours, with cell death 
assessed by trypan blue exclusion (Fig. 1A in II). The data revealed that Nutlin-3 
treatment resulted in a two- to six-fold higher, time-dependent induction of cell death 
than in the vehicle-treated control (Fig. 1A in II). To study whether Nutlin-3 activity in 
PEL tumors coincides with an increased expression of p53 and its targets MDM2 and 
p21CIP1, we performed Western blotting analysis that detected an increase in 
expression of p53 and of its targets in Nutlin-3-treated PEL tumors (Fig. 1B in II). As 
Nutlin-3 has been reported to trigger apoptosis in primary tumor samples from 
hematological malignancies (Kojima et al., 2005; Stuhmer et al., 2005; Coll-Mulet et 
al., 2006; Secchiero et al., 2006), we examined its apoptotic potential also in clinical 
PEL tumors. Immunoblotting analysis revealed elevated levels of active caspase-3 in 
PEL tumors upon Nutlin-3 treatment, suggesting efficient execution of apoptosis (Fig. 
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1B in II). Taken together, these results suggest that the downstream p53-dependent 
pathway is intact also in primary PEL tumors.   
 
Compared to our control BC-3 cells, the apoptotic response of one clinical PEL tumor 
(#993) was delayed (Fig. 1A in II). Given our finding that LANA is in a complex with 
p53 and MDM2 (I), and that it most likely contributes to the specificity of Nutlin-3-
induced cell death in the KSHV-infected cells (I, and (Koopal et al., 2007)), we 
examined LANA expression level in the #993 tumor (II). Indeed, immunoblotting 
analysis revealed reduced LANA levels in this tumor when compared to the other 
tumor (#974) and to BC-3 cells (Fig. 1B in II). This prompted us to search for any 
correlation between levels of LANA and response to Nutlin-3 treatment (II). To this 
end, we subjected U2OS cells stably expressing LANA or GFP from lentiviral 
constructs to Nutlin-3 (7 µM) treatment and determined cell viability by the trypan 
blue exclusion (Fig. S1 in II). We found that the Nutlin-3-induced cytotoxic effect in 
U2OS cells expressing LANA was almost three-fold higher than in the control cells 
expressing GFP (Fig. S1 in II). Based on these results, we suggest that LANA 
expression may promote sensitivity of the cells to the cytotoxic activity of Nutlin-3. 
However, further studies are required to confirm this observation in a broader panel of 
PEL cells. A possible in vivo validation of the correlation between LANA levels and 
Nutlin-3 cytotoxicity could be carried out in LANA transgenic animals with B-cell 
tumors (Fakhari et al., 2006) that resemble the B-cell population of KSHV-associated 
human lymphomas (Jenner et al., 2003; de Sanjose et al., 2004).  
 
2.4. Viral lytic replication impairs the apoptotic potential of Nutlin-3 in vivo 
One of the major challenges for effective therapy against cancer in general is to 
overcome tumor resistance. Our in vivo data (see 2.1. and 2.2.) demonstrate that the 
overall response rate to Nutlin-3 treatment was excellent. However, four mice 
responded poorly to Nutlin-3 (Fig. 3A in II). In order to study the mechanism behind 
their poor response, we collected and further analyzed their ascites. 
Immunofluorescence analysis of tumor cells from one non-responder mouse revealed 
impaired stabilization of p53 and no activation of its target p21CIP1, unlike the 
response in the responder mouse (Fig. 3C in II). To examine whether absence of p53 
pathway activation in tumor cells from the non-responder mouse leads to a failure of 
these cells to undergo apoptosis, we performed TUNEL and anti-active caspase-3 
immunostaining (Fig. 3D in II). No positive staining was detectable in tumor cells of 
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the non-responder mouse, sharply contrasting with cells of the responder mouse (Fig. 
3D in II). These results suggest that in the tumors of the non-responder mice, the 
apoptotic response was compromised. 
 
2.4.1 KSHV viral reactivation attenuates the p53-dependent apoptotic response to 
MDM2 inhibition  
Because these results suggest that LANA expression sensitizes cells to the cytotoxic 
effect of Nutlin-3, we first examined whether LANA expression levels differ between 
responder and non-responder mice (Fig. 3B in II). However, Western blotting analysis 
failed to reveal any substantial reduction in LANA in the non-responders (Fig. 3B in 
II). 
 
As rapid progression and dissemination of KS lesions have been linked to the extent of 
viral reactivation and viral loads in the peripheral blood (Whitby et al., 1995; 
Brambilla et al., 1996; Campbell et al., 2000; Pellet et al., 2002; Quinlivan et al., 
2002; Campbell et al., 2003; Engels et al., 2003; Song et al., 2004; Guttman-Yassky et 
al., 2007; Laney et al., 2007; Mancuso et al., 2008), we decided to assess the viral 
replication phase in the PEL tumors from ascites of responder and non-responder mice 
(Fig. 3E in II). Our quantitative real-time PCR (qRT-PCR) analysis for expression of 
the KSHV lytic transcripts ORF50 (immediate early lytic gene) and K8.1 (late lytic 
gene) showed that expression of both lytic transcripts was markedly higher in non-
responder mice than in responders (Fig. 3E in II). This clearly correlates with the 
response of these mice to the Nutlin-3 treatment and to their tumor burden (Fig. 3A in 
II). Collectively, these results suggest that viral lytic reactivation may affect the 
outcome of small-molecule-mediated p53 restoration in vivo.  
 
2.5 Chemical and physiological induction of viral reactivation recapitulates 
resistance to MDM2 inhibition in vitro 
Inspired by the unexpected finding of elevated lytic gene expression in the tumors, we 
tried to recapitulate the attenuation of the Nutlin-3 response by viral reactivation in 
vitro (II). Since KSHV-infected cells can be induced to enter the productive replication 
phase by a variety of chemicals (Yu et al., 1999; Miller et al., 2007), we induced lytic 
replication in PEL cells (BC-3 and JSC-1) with TPA. Following TPA-induced viral 
reactivation, the cells were treated with Nutlin-3 and analyzed by Western blotting 
(Fig. 4A in II), revealing a four-fold lowering of the stabilization of p53 levels in TPA- 
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and Nutlin-3-treated BC-3 and JSC-1 cells, in contrast to Nutlin-3-treated uninduced 
PEL cells. Importantly, this decrease in p53 levels was not due to an adverse TPA 
effect, because TPA- and Nutlin-3-treated KSHV-negative lymphoblastoid cells IHE 
showed no p53 attenuation (Fig. S4 in II). Furthermore, as determined by trypan blue 
exclusion, induction of lytic replication in both BC-3 and JSC-1 cells led to a 
significantly impaired apoptotic response to Nutlin-3 treatment (Fig. 4C in II).  
 
We next studied the role of lytic replication in the impaired apoptotic response to 
Nutlin-3 treatment in a more physiological setting. Hypoxic conditions have induced 
KSHV lytic replication (Davis et al., 2001; Haque et al., 2003; Cai et al., 2006; Haque 
et al., 2006). Moreover, as PEL lymphomas arise in a low-oxygen environment 
(Funahashi et al., 1971; Houston, 1981), hypoxia may predispose the tumor cells to 
induction of lytic replication. We thus studied the effect of hypoxia-induced viral 
reactivation on the apoptotic response to Nutlin-3 treatment (II). To this end, BC-3 and 
JSC-1 cells were cultured under hypoxic conditions (1% O2) for 96 hours, and 
analyzed for viral reactivation by immunostaining for early lytic marker ORF59. 
Quantitative immunofluorescence analysis of hypoxia-treated PEL cells revealed 
enhanced spontaneous lytic replication, as compared to PEL cells cultured in a 
normoxic (21% O2) environment (Fig. 5A in II). To examine whether hypoxia-induced 
viral reactivation affects p53 expression, we performed immunoblotting analysis of 
Nutlin-3- or vehicle-treated JSC-1 cells grown under hypoxic or normoxic conditions. 
Under low oxygen conditions, both the basal level of p53 and its stabilization in 
response to Nutlin-3 treatment were lower than in normoxia-treated cells (Fig. 5E in 
II).  
 
To investigate whether the impaired apoptotic response to Nutlin-3 treatment depends 
on hypoxia-induced viral reactivation, we cultured BC-3 and JSC-1 cells under 
hypoxic conditions for 18 hours, followed by Nutlin-3 treatment for an additional 48 
hours. A trypan blue exclusion viability assay showed a dramatic decrease in Nutlin-3-
induced cell death in the hypoxia-reactivated PEL cells (Fig. 5B in II).  Next, we 
investigated whether inhibition of viral reactivation with anti-herpes agent GCV 
(Kedes and Ganem, 1997), a specific inhibitor of KSHV replication, could restore the 
apoptotic potential of Nutlin-3 in hypoxia-reactivated PEL cells. We therefore 
incubated hypoxia-treated JSC-1 cells with GCV or vehicle control for 48 hours, 
followed by co-incubation with Nutlin-3 for the next 72 hours. Intriguingly, inhibition 
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of late lytic gene expression by GCV (Fig. 5C in II) resulted in robust restoration of 
Nutlin-3-induced cell death, as determined by the trypan blue exclusion method (Fig. 5 
D in II). These results demonstrate that in PEL cells, KSHV viral reactivation 
compromises Nutlin-3-induced cytotoxicity. However, this undesirable outcome can 
be prevented by inhibition of lytic replication.  
 
Cancer-cell resistance to therapeutic agents can be multifaceted, and understanding its 
causes is fundamental to improving already-existing therapies and to developing new, 
more efficient treatment strategies. Our data uncover the role of viral lytic replication 
in the therapies based on p53 restoration (II). Anti-virals for KSHV-associated diseases 
in humans are essential in patients with advanced AIDS; GCV treatment causes a rapid 
and dramatic decline in the prevalence of new KS tumors (Glesby et al., 1996; Mocroft 
et al., 1996; Martin et al., 1999). The search for new treatments against KSHV-
associated malignancies has become intertwined with the identification of genes and 
their products that directly contribute to the malignancy. Recently, a novel role for 
Ser/Thr Pim kinases in KSHV pathobiology has been reported, demonstrating that 
Pim-1 and Pim-3 are required for viral lytic reactivation at very early stages (Cheng et 
al., 2009); as these two kinases thus may contribute also to PEL tumor development, it 
may be feasible to selectively inhibit these kinases to avoid any resistance of PEL 
tumors to specific treatments. However, before a potential Pim kinase inhibitor can be 
considered, one needs to evaluate its cytotoxicity and its ability to specifically inhibit 
kinase activity and lytic replication. A leading inhibitor for Pim kinases should thus 
first be tested for suppression of early stages of viral lytic reactivation in PEL cells in 
vitro, and then in the i.p. PEL mouse model to assess whether even higher therapeutic 
efficacies are possible in combination with the MDM2 inhibitor. 
 
2.6 Decrease in p53 protein level in lytic PEL cells is proteasome-mediated 
As the ubiquitin-proteasome pathway is an important system to control the half-life of 
various proteins including transcription factors such as p53 (Haupt et al., 1997; 
Kubbutat et al., 1997; Muratani and Tansey, 2003), we studied whether the decrease in 
the level of p53 in lytically reactivated PEL cells (see 2.5 and Fig. 5E in II) results 
from its degradation by the ubiquitin-proteasome system. We thus preincubated JSC-1 
cells in hypoxia and then monitored changes in their p53 protein upon treatment with 
the 26S proteasome inhibitor MG132 or DMSO. Western blotting revealed that these 
hypoxia-treated JSC-1 cells displayed decreased turnover of p53 in the presence of 
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MG132, suggesting that reduction in p53 protein levels in lytically reactivated JSC-1 
cells (see 2.5 and II) is proteasome-mediated (Fig. 5E in II).  
 
To discover which E3 ubiquitin ligase(s) will specifically mark p53 for enhanced 
proteasomal degradation in PEL cells upon KSHV viral reactivation, we examined 
whether MDM2 could mediate this degradation. To this end, we monitored changes in 
MDM2 levels in hypoxia- or normoxia-treated JSC-1 cells upon Nutlin-3 treatment. 
Western blotting showed that Nutlin-3 raised the levels of MDM2 protein in normoxia-
treated cells, but no increase in MDM2 was detectable in hypoxic cells undergoing 
lytic replication (Fig. 5E in II). Thus, although MDM2 predominantly controls the 
amount of p53 protein during the latent infection, after the switch to lytic replication, 
another E3 ligase is most likely involved in the ubiquitin-mediated proteasomal p53 
degradation. 
 
Several KSHV proteins have been identified in the regulation of p53 stability. The 
BZLF1 protein of EBV, which functions as an adaptor component of the ECS 
ubiquitin ligase complex, enhances the ubiquitin-mediated degradation of p53 (Sato et 
al., 2009a; Sato et al., 2009b). Interestingly, KSHV encodes a homolog of BZLF1, a 
lytic protein K-bZIP, which belongs to the basic region-leucine zipper (bZIP) family of 
transcription factors (Lin et al., 1999). Recently, K-bZIP has been demonstrated to 
possess activity of the SUMO E3 ligase, with specificity towards SUMO2/3 (Chang et 
al., 2009) and to interact with and inhibit p53-driven transcription in PEL cells (Park et 
al., 2000). Further studies are required to clarify whether K-bZIP targets p53 for 
proteasomal degradation during the lytic replication phase. An alternative mechanism 
of p53 degradation may involve proteins that themselves lack E3 ligase activity, such 
as immunomodulatory KSHV lytic proteins (vIRFs). These vIRFs could theoretically 
form multi-protein complexes with ubiquitin ligase activity components. Accordingly, 
vIRF-4 has recently been shown to interact with MDM2 and to facilitate the 
proteasome-mediated degradation of p53 (Lee et al., 2009a), whereas vIRF-1 has been 
reported to interact with p53 and inhibit its phosphorylation and acetylation (Lin et al., 
2001; Seo et al., 2001; Shin et al., 2006). As these events may lead to ubiquitination 
and degradation of p53, the role of vIRF-1 and of vIRF-4 in p53 degradation upon lytic 
replication requires examination. 
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3. The switch from latency to lytic replication - a critical step in the 
KSHV pathogenesis (III, IV; unpublished data) 
Latency provides a unique opportunity for KSHV to escape host immune surveillance 
and to establish persistent infection (Coscoy, 2007). However, to maintain viral 
reservoirs and to spread to other sites and hosts, KSHV must reactivate from latency 
and enter the lytic growth phase to generate more viral progeny. The switch between 
the latent phase and lytic replication is therefore a critical step determining the 
outcome of viral infection and influencing the pathogenesis of KSHV-induced 
malignancies. Viral reactivation can be induced and studied in KSHV-infected B-type 
lymphocytes in cell culture, but our current knowledge of specific virus-host 
interactions that repress or activate lytic replication is still limited.  
 
3.1 Nucleophosmin is a novel regulator of the latent-lytic switch 
3.1.1 Nucleophosmin is phosphorylated by v-cyclin-CDK6 in vivo in PEL cells 
As transient expression of v-cyclin causes NPM redistribution from nucleolus to 
nucleoplasm in transfected U2OS osteosarcoma cells (Kurki et al., 2004), we studied 
the localization of NPM in naturally KSHV-infected PEL cells (IV). As 
immunofluorescence analysis revealed NPM in both nucleoplasm and nucleolus in 
PEL cells (data not shown in IV), we investigated whether v-cyclin and NPM could 
have a functional relationship in vivo in a biologically relevant KSHV model.  
 
To this end, we needed to develop a biochemical approach to identify and further 
characterize the functional relationship between v-cyclin and its in vivo cellular 
interaction partners in PEL cells. We summarize here the development and validation 
of the methodology described in detail in Study III. As the results were not within the 
scope of this thesis, they are not discussed in detail.  
 
As a first step to study v-cyclin interaction partners in vivo we generated a new 
affinity-purified polyclonal antibody against v-cyclin protein (III). This antibody we 
tested for its ability to specifically and efficiently recognize full-length v-cyclin protein 
in native and denatured conditions by immunoblotting and immunoprecipitation. This 
antibody served to identify v-cyclin substrates in all subsequent steps: (1) by gel 
filtration chromatography, and fraction analysis by immunoblotting, (2) 
immunoprecipitation of v-cyclin from v-cyclin-containing fractions, and (3) 
determination of v-cyclin kinase activity towards the co-precipitated endogenous 
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proteins (III). By this approach, we were able to confirm in vivo in PEL cells an earlier 
observation that p27KIP1 is a substrate for the v-cyclin-CDK6 complex in vitro (Ellis 
et al., 1999; Mann et al., 1999)(III).  
 
Given the applicability of this methodology (III and Jarviluoma et al., 2006), we went 
on to investigate whether NPM forms a complex with v-cyclin and becomes 
phosphorylated by v-cyclin-CDK6 in PEL cells (IV). To accomplish this, PEL cells 
were fractionated by gel filtration chromatography, and the fractions containing NPM 
and v-cyclin identified. These fractions were subjected to immunoprecipitation and a 
subsequent in vitro kinase assay towards the coprecipitated proteins. This revealed an 
approximately 37-kDa band at the position of NPM on the SDS-PAGE gel, which was 
phosphorylated by the v-cyclin-associated CDK6 kinase (Fig. S1A-C in IV). This 
strongly suggests that NPM may be a novel v-cyclin target in PEL cells in vivo. 
 
NPM phosphorylation by v-cyclin–CDK6 in vitro occurs mostly on Thr199 (Cuomo et 
al., 2008). We confirmed this finding in our experimental in vitro system by 
transfecting U2OS cells with expression vectors for v-cyclin or a vector control 
together with wt NPM (eGFP-NPM), or its phosphorylation site mutant T4A 
(Thr199Ala, Thr214Ala, Thr234Ala, Thr237Ala) and mutant T3A in which all but 
Thr199 is replaced by Ala (Fig. S1D in IV). We analyzed phosphorylation of NPM by 
immunoblotting with phospho-NPM antibody (pNPM Thr199). This analysis revealed 
that phosphorylation of NPM was detectable only in cells co-transfected with v-cyclin 
and with the eGFP-NPM retaining an intact Thr199 site (Fig. S1D in IV).  
 
To demonstrate that NPM phosphorylation in KSHV-infected cells was indeed v-
cyclin-dependent, we silenced v-cyclin expression in SLK endothelial cells stably 
infected with the recombinant rKSHV.219 (Vieira and O'Hearn, 2004), using 
retrovirus-mediated RNA interference (RNAi) (IV). Immunoblotting analysis showed 
an approximately five-fold lower NPM phosphorylation on Thr199 in cells with stably 
down-regulated v-cyclin (sh-v-cyclin-expressing cells) than for the control (sh-scr) 
cells (Fig. 1A in IV). RNAi against v-cyclin triggers a concomitant depletion of  
v-FLIP (Godfrey et al., 2005), because v-FLIP translation is carried out from a 
bicistronic transcript (comprised the ORF72/v-cyclin and ORF71/v-FLIP genes) 
through an internal ribosome entry site located in the v-cyclin coding region (Talbot et 
al., 1999; Bieleski and Talbot, 2001; Grundhoff and Ganem, 2001). We therefore 
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needed to eliminate the possibility that inhibition of NPM phosphorylation in sh-v-
cyclin-expressing cells is due to the loss of v-FLIP. To accomplish this, rKSHV.219 
SLK cells expressing sh-v-cyclin were reconstituted for v-FLIP by use of retrovirus-
mediated gene transfer. The RT-qPCR analysis revealed that expression of sh-v-cyclin 
reduced the levels of both v-cyclin and v-FLIP transcripts (Fig. S3A in IV). Based on 
our immunoblotting result, this reduction was accompanied by a substantial decrease 
in NPM Thr199 phosphorylation in the sh-v-cyclin cells expressing either the empty 
control vector (pBMN) or v-FLIP (v-FLIP-pBMN) (Fig. S3B in IV). These data 
suggest that for NPM phosphorylation on Thr199, v-cyclin but not v-FLIP is required.  
 
As CDK6 has been identified as a predominant kinase partner for v-cyclin (Chang et 
al., 1996; Godden-Kent et al., 1997; Li et al., 1997; Platt et al., 2000), we further 
delineated whether CDK6 is required for v-cyclin-mediated phosphorylation of NPM. 
To accomplish this, we silenced CDK6 in rKSHV.219-infected EA.hy926 endothelial 
cells, and, in addition, CDK4 or CDK6 in BC-3 cells by lentivirus-mediated RNAi, as 
detailed in Methods. Immunoblotting analysis showed markedly attenuated NPM 
phosphorylation on Thr199 in both endothelial and BC-3 cells silenced for CDK6 as 
compared to the CDK4-silenced and non-silenced controls (Fig. 1B-D in IV). This 
indicates that in KSHV-infected endothelial and PEL cells, the v-cyclin-CDK6 
complex mediates the NPM phosphorylation on Thr199. 
 
3.1.2 Phosphorylation of NPM promotes the NPM-LANA association, which is 
further regulated by acetylation  
Transcripts of v-cyclin and LANA are generated from a common promoter (Dittmer et 
al., 1998; Talbot et al., 1999). As NPM has been reported to interact with LANA and 
the terminal repeats of the KSHV genome in PEL cells (Si et al., 2006), and we found 
that NPM interacts with v-cyclin (Fig. S1B in IV), we studied the role of v-cyclin in 
the formation of the NPM-LANA complex in more detail. We transfected U2OS cells 
stably expressing LANA or GFP with an Myc-tagged v-cyclin expression vector 
(Myc-v-cyclin) or with an empty vector as a control. Cell extracts were subjected to 
immunoprecipitation with anti-LANA or anti-NPM antibodies. Immunoblotting 
analysis revealed that transient transfection of v-cyclin in U2OS cells stably expressing 
LANA, but not GFP, resulted in the NPM-LANA complex formation (Fig. 2A in IV).  
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To investigate whether NPM-LANA interaction in PEL cells is CDK6-dependent, we 
silenced CDK6 in BC-3 cells by lentiviral RNAi (IV). Cell lysates were subjected to 
gel filtration chromatography, and NPM/LANA-positive fractions were further 
immunoprecipitated with anti-LANA antibody. Immunoblotting showed that silencing 
of CDK6 in BC-3 cells reduced interaction of NPM with LANA (Fig. 2B in IV), 
indicating that v-cyclin-CDK6 kinase activity is required for the NPM-LANA complex 
formation (Fig. 6). 
 
Given that Thr199 is the major phosphorylation site on NPM (Fig. S1D in IV), we 
examined the importance of NPM phosphorylation on Thr199 for the NPM-LANA 
interaction. We ectopically expressed in U2OS cells stably expressing LANA,  
v-cyclin, along with the wild-type NPM (eGFP-NPM) or its phosphosite mutants that 
were harboring Thr to Ala mutations of NPM codons. Western blotting analysis of 
LANA immunoprecipitates showed that only NPM with an intact phosphorylation site 
at Thr199 was associated with LANA  (Fig. 3B in IV). Thus, NPM phosphorylation on 
Thr199 by v-cyclin-CDK6 seems to be required for efficient NPM-LANA interaction.   
 
Maintenance of the KSHV latency is associated with deacetylation of the chromatin 
due to recruitment and activity of HDACs (Miller et al., 2007; Pantry and Medveczky, 
2009). As NPM associates with histones (Okuwaki et al., 2001b) and changes 
chromatin structure by HDAC recruitment (Liu et al., 2007a), we examined whether 
NPM associates with HDAC1 in PEL cells (IV). We thus reciprocally 
immunoprecipitated BCBL-1 whole-cell extracts with anti-HDAC1 or anti-NPM 
antibodies. Immunoblotting analysis revealed NPM in a complex with HDAC1 in 
latent BCBL-1 cells (Fig. 3C in IV). Furthermore, this complex greatly dissociated in 
the presence of NaB, a histone deacetylase inhibitor that induces viral reactivation 
(Fig. 3C in IV). To examine whether LANA also forms a complex with HDAC1, we 
subjected HDAC1 immunoprecipitates to immunoblotting with anti-LANA antibody, 
detecting the complex in latent BCBL-1 cells and demonstrating that it was NaB-
resistant (Fig. 3D in IV). We therefore examined whether NPM could affect the 
integrity of the LANA-HDAC1 complex. To this end, we silenced NPM in PEL cells 
by use of lentivirus-mediated RNAi. Cell extracts were subjected to 
immunoprecipitation with anti-HDAC1 antibody, and immunoblotting analysis 
revealed that NPM silencing abolished the interaction of LANA and HDAC1 (Fig. 3D 
in IV). This suggests that in latently infected PEL cells, NPM recruits HDAC1 and 
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allows its interaction with LANA, and possibly with core histones (Fig. 6). In 
agreement with this, HDACs have been demonstrated to associate with lytic ORF50 
promoter and to contribute to its stable repression, thereby inhibiting lytic gene 
expression (Gwack et al., 2001; Lu et al., 2003).  
 
Inhibition of the HDAC activity induces lysine acetylation of LANA, its dissociation 
from the core histones, and transcriptional de-repression of the ORF50 promoter (Lu et 
al., 2006). Since NPM silencing abolished HDAC1-LANA interaction (IV and Fig. 6), 
we determined LANA acetylation status upon NPM silencing. We immunoprecipitated 
NPM-silenced BCBL-1 cell extracts with anti-acetylated lysine (Ac-K) antibody. 
Western blotting analysis with LANA revealed a remarkable increase both in the 
intensity and appearance of newly acetylated LANA bands when compared to those of 
the non-silenced control (Fig. 3E in IV). Thus, depletion of NPM led to enhanced 
LANA acetylation (Fig. 6).  
 
The p300-mediated acetylation of NPM is required for nucleosomal disassembly and 
for active chromatin transcription (Swaminathan et al., 2005). We therefore analyze 
the extent of NPM acetylation in BC-3 cells in the presence or absence of the histone 
deacetylase inhibitor NaB (IV). Immunoblotting analysis, with anti-Ac-K antibody, of 
NPM immunoprecipitates showed elevated NPM acetylation upon HDAC inhibition 
(Fig. 3F in IV). In order to examine whether inhibition of HDAC activity promotes 
association of NPM with p300, we performed NPM immunoprecipitation from BCBL-
1 cells treated with NaB. Western blotting demonstrated that NaB treatment enhanced 
NPM-p300 interactions (Fig. 3G in IV). 
 
Because protein acetylation modulates the interaction between LANA and NPM, we 
examined whether NaB could affect this interaction (IV), by treating BCBL-1 cells 
with NaB or vehicle control, then by subjecting their lysates to immunoprecipitation 
with anti-LANA antibody. Immunoblotting analysis showed that association of NPM 
with LANA was abolished in the presence of NaB (Fig. 3H in IV), suggesting that 
protein acetylation controls the interaction between NPM and LANA (Fig. 6). Lysine 
acetylation has been reported to impair phosphorylation-dependent interactions of 
large macromolecular complexes (Choudhary et al., 2009). Our results thus suggest 
that the initial association of NPM with LANA is regulated by v-cyclin-mediated 
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phosphorylation of NPM, and is further controlled by lysine acetylation  
(Fig. 6).  
 
3.1.3 Silencing of NPM leads to viral reactivation 
As we had demonstrated that NPM silencing induces an increase in PEL-cell LANA 
acetylation (Fig. 3E in IV), and acetylation of LANA has been linked to viral 
reactivation (Lu et al., 2006), we next examined the expression of lytic replication 
markers in NPM-silenced PEL cells (IV). These NPM-silenced BC-3 and BCBL-1 
cells were analyzed by immunofluorescence using antibody against an early lytic 
marker, ORF59. Silencing of NPM led to an increase in ORF59-positive cells as 
compared to those in the non-silenced control (Fig. 4A-B in IV). The qRT-PCR 
analysis of NPM-silenced BCBL-1 cells for lytic genes (ORF50, ORF57, and K8.1) 
corroborated further these results (Fig. 4C in IV), suggesting that viral reactivation was 
induced in response to NPM silencing. 
 
Because production of new viral particles is the final event in the lytic replication 
cascade, we investigated the production and release of infectious virions in response to 
NPM silencing. We therefore transduced BCBL-1 cells with lentivirus expressing 
short hairpin RNA (sh-RNA) against either NPM (sh-NPM) or a non-target control 
(sh-Scr) (IV). Western blot analysis revealed that silencing of NPM dramatically 
induced expression of the late lytic glycoprotein K8.1, whereas transduction with a 
scrambled control had no effect (Fig. 4D in IV). Next, we confirmed that the observed 
increase in K8.1 expression corresponded to the production of infectious KSHV 
virions. To this end, we used supernatants of BCBL-1 cells stably expressing sh-RNA 
against NPM to infect naive SLK endothelial cells (IV). Immunofluorescence studies 
revealed a great number of LANA-positive cells in the infected SLK target population, 
two days post-infection, confirming that NPM silencing resulted in efficient 
production and release of infectious viral particles (Fig. 4E-F in IV). In addition, when 
we used concentrated virus (obtained by ultracentrifugation of supernatants of BCBL-1 
cells stably expressing sh-RNA against NPM) to infect SLK cells, the intensity of the 
LANA signal and the number of nuclear speckles typical for the LANA 
immunostaining greatly increased (Fig. 4E in IV). Considered together, these data 
confirm induction of the KSHV full lytic cascade in cells depleted for NPM 
expression. Based on other reports and our findings in this thesis (3.1.2, 3.1.3, and IV) 
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we suggest a model of NPM as a critical regulator of the KSHV latent-lytic switch 
(Fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. NPM as a novel regulator of the KSHV latent-lytic switch. This schematic model depicts 
the role of NPM and acetylation in the regulation of KSHV replication. In latency, NPM is 
phosphorylated by v-cyclin-CDK6, and this phosphorylation is necessary for NPM association wih 
LANA. The NPM-LANA complex is bound to chromatin and recruits HDACs to the immediate/early 
lytic promoters. This is essential to maintain the transcriptional repression of viral lytic genes. 
Following treatment with an HDAC inhibitor, NaB, NPM and LANA are acetylated, and the LANA-
NPM complex dissociates, leading to viral reactivation. Similarly, silencing of NPM leads to an increase 
in the LANA acetylation and its dissociation from Sp1 and core histones, which facilitates viral 
reactivation. Both NPM depletion and NaB treatment are associated with an increase in the acetylation 
of LANA and Sp1. This may lead to derepression of the ORF50 promoter through decreased LANA 
occupancy at the ORF50 promoter regulated by interactions with Sp1 and with core histones or may 
lead to dissociation of LANA from the RBP-Jk sites. HDACs: histone deacetylases (Adapted and 
modified from SABiosciences, 2009).  
 
3.2. Phosphorylation of NPM on Thr199 correlates with KSHV latency 
Since v-cyclin promoted NPM-LANA interaction, we examined whether there existed 
any correlation between levels of v-cyclin, pNPM Thr199, and spontaneous viral 
reactivation in PEL cells (IV). Western blotting analysis, performed on total PEL cell 
extracts, revealed a correlation between phosphorylated NPM and v-cyclin expression 
levels (Fig. 5A in IV). To investigate whether NPM phosphorylation indeed 
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contributes to the interaction between NPM and LANA, we performed LANA 
immunoprecipitation from extracts of JSC-1 and BC-3 cells. We found a reduced 
amount of NPM complexed with LANA in JSC-1 cells, which express a low level of 
pNPM Thr199, in contrast to BC-3 cells expressing a high level of pNPM Thr199 (Fig. 
5B in IV). To examine whether NPM phosphorylation correlates with extent of viral 
reactivation, we performed a qRT-PCR analysis for lytic transcripts ORF50 and 
ORF57. Interestingly, the level of endogenous pNPM Thr199 inversely correlated with 
the spontaneous expression of both lytic markers (Fig. 5C in IV). The cells with lower 
pNPM Thr199 levels had higher levels of spontaneous expression of the lytic markers 
than did cells with elevated pNPM Thr199 (Fig. 5C in IV). These results thus suggest 
that the phosphorylation of NPM on Thr199 may play a key role in regulating of viral 
latency. 
 
Finally, we should consider the clinical implications of the results obtained. Despite 
major improvements in the treatment of KSHV-associated malignancies, overall 
survival of patients remains poor, making new prognostic markers and therapeutic 
strategies urgently needed. Apart from the potential diagnostic value of measuring 
KSHV viral loads by routine PCR assays, or by serological methods mainly used to 
differentiate KS from its mimics, the lack of any reliable prognostic factor able to 
predict patient outcome complicates potential therapies. Because we could detect 
pNPM Thr199 both in PEL cells (Fig. 5A in IV) and in biopsies from KS patients  
(Fig. 6 in IV), and the phosphorylation of NPM on Thr199 correlated with extent of 
viral reactivation (Fig. 5C-D in IV), one could suggest pNPM Thr199 as a prognostic 
factor for progression of KSHV-associated diseases. This phosphorylation could 
therefore be analyzed in early (patch/plaque) and late (nodular) tumor stages of the 
AIDS-related and endemic KS clinical forms, in relation to tumor aggressiveness and 
viral loads in these lesions. Although further studies need to validate pNPM Thr199 as 
a prognostic factor, our results provide a proof of principle for the investigation of 
more accurate markers for the recognition of patients at higher risk.  
 
3.3 NPM phosphorylation is required for efficient establishment of latency 
(unpublished data) 
The relationship between viral latency and extent of NPM phosphorylation on Thr199 
inspired us to investigate whether the Thr199 phosphorylation on NPM plays a role in 
the establishment of latency upon de novo KSHV infection.  
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To this end, we silenced by lentivirus-mediated RNAi, CDK6 in EA.hy926, and CDK6 
or CDK4 in SLK endothelial cells. Cells were then infected with rKSHV.219, and the 
number of LANA-positive cells was determined by immunofluorescence with anti-
LANA antibodies as a measure of latent infection starting at four days after infection, 
and analyzed on every other day until day ten. As early as day four, the KSHV-
infected, CDK6-silenced (sh-CDK6) Ea.HY926 and SLK cells showed about 30% 
fewer LANA-positive cells than did the non-silenced (sh-Scr) or CDK4-silenced (sh-
CDK4) control cells (Fig. 7A). In line with previous studies (Grundhoff and Ganem, 
2004), we observed a decline in the number of LANA-positive cells in all cell lines 
analyzed (Fig. 7A). These results suggest that inhibition of NPM phosphorylation in 
CDK6-silenced cells affects the establishment of latency, but not the rate of KSHV 
episome loss. Interestingly, immunoblot analysis revealed that the level of NPM 
Thr199 in the non-silenced control cells increased from day six to day eight post-
infection and remained elevated until day ten (Fig. 7C-D). This increase correlated 
with an increase in the protein levels of CDK6 (Fig. 7C-D), which may suggest that 
KSHV infection induces CDK6 stabilization in the course of infection. Comparable 
results also came from NPM-silenced cells (data not shown), which further supports 
the role of NPM phosphorylation in the establishment of KSHV latency. 
 
We also addressed the effect of CDK6 silencing on KSHV genome copy number in the 
latently infected rKSHV.219-EA.hy926 and rKSHV.219-SLK cells at four days post-
infection (p.i.). To validate the method for analyzing genome copy numbers, we 
performed a qRT-PCR analysis using DNA derived from BCBL-1 cells. The average 
number of episomes in this cell line was approximately 67 copies (data not shown), 
and is in accordance with previous results (Lallemand et al., 2000; Cai et al., 2005). 
The qRT-PCR analysis of the KSHV-infected CDK-silenced endothelial cells 
demonstrated that silencing of the expression of CDK6, but not of CDK4, led to a 
striking reduction in the KSHV copy numbers by 80% in EA.hy926 and 53% in SLK 
cells at day four after infection (Fig. 7B).  
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Figure 7. CDK6 silencing reduces the efficiency of establishment of KSHV latency in endothelial 
cells. (A) EA.hy926 cells expressing control sh-Scr or sh-CDK6 (left panel) and SLK cells expressing 
control sh-Scr, sh-CDK6, or sh-CDK4 (right panel) were infected with rKSHV.219 and analyzed for 
LANA expression by immunofluorescence at indicated time-points. Infection efficiency in EA.hy926 
and SLK cells expressing control sh-RNA was set at 100%. The graph shows normalized percentage of 
LANA-positive cells relative to infection level in sh-Scr expressing cells. (B) The sh-Scr and sh-CDK6-
expressing cells used in A were assayed for the abundance of KSHV genome copies by qRT-PCR.  
Each value represents the mean of two independent experiments ± SD. Western blot analysis of a time-
course of rKSHV.219-infected EA.hy926 (C) and SLK (D) cells used in panel A. Whole cell extracts 
were subjected to SDS-PAGE, followed by immunoblotting and analysis for pNPM (Thr199), total 
NPM, CDK6, CDK4, and Cyclin A. Tubulin served as a loading control.  
 
The ability of KSHV to establish and maintain latency in the host enables this virus to 
successfully persist in cells of endothelial and lymphoid lineages, from which it can 
later reactivate and thus complicate disease outcome or response to therapies. We 
showed that phosphorylation of NPM on Thr199 is a prerequisite for NPM-LANA 
interactions which allow recruitment of HDACs and maintenace of the latent infection 
(IV). Identification of cellular factors that mediate the establishment of latency may 
provide potential targets for the improvement of anti-viral strategies: preventing or 
inhibiting this process and the dramatic consequences that arise from viral reactivation 
from latency. Concerning clinical use, these approaches could include development of 
specific CDK-6 inhibitors, NPM antagonists, or RNA aptamers  
(Qi et al., 2008; Jian et al., 2009) targeting latency in KSHV-induced cancers. 
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Approximately 15% of human cancers globally are related to viral infection.  
KSHV is consistently associated with KS, the most widespread cancer in patients with 
AIDS and a primary cause of cancer deaths in Africa. In addition, KSHV causes 
devastating lymphoproliferative disorders such as PEL and MCD. 
 
This thesis work evaluates the functional consequences of p53 restoration by MDM2 
inhibition in KSHV-induced lymphomas. The ability of the MDM2 antagonist  
Nutlin-3 to effectively restore p53 function and eradicate PEL tumor cells was 
demonstratable both in vitro and in vivo. In mice, the notable anti-tumor effect in PEL 
tumors in combination with minimal side-effects suggests that restoration of p53 is  
a valuable, novel treatment modality for KSHV-induced malignancies. Although the 
strategy of targeting the p53-MDM2 interaction appears to be a promising to combat 
PEL malignancies, clinical trials are necessary to completely evaluate the efficacy and 
risks of MDM2 inhibition in these lymphomas. Restoration of p53 function has led to 
impressive anti-neoplastic activities in several models of common human cancers.  
In addition, inhibition of p53-MDM2 interaction has been suggested as a therapy for 
malignancies associated with extensive angiogenesis. Thus, pharmacological inhibition 
of MDM2 calls for evaluation of its applicability also in appropriate preclinical KS 
models. In fact, restoration of p53 could be tested either in mice bearing s.c. xenografts 
of KSHV-transformed endothelial cells or in a recently reported mouse model in which 
KS-like tumors form upon introduction of a recombinant GFP-expressing KSHV into 
murine bone marrow endothelial-lineage cells (Mutlu et al., 2007). 
  
The future of MDM2 inhibition as a treatment against KSHV-associated cancers will 
largely depend on successful development of targeted combinatorial therapies.  
The data presented here implicate viral reactivation as a factor, which can hamper the 
apoptotic response of p53 restoration in vivo. This further underscores the importance 
of identifying critical factors involved in the latent-lytic switch of KSHV. This study 
identified NPM as a novel cellular regulator of KSHV replication, meaning that NPM 
or inhibition of its Thr199 phosphorylation may thus represent attractive, novel targets 
for intervention. Knowledge achieved thus far suggests the potential for a combination 
treatment in which MDM2 inhibition would be combined with drugs that inhibit viral 
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reactivation even at very early stages. Promising drug candidates against viral 
reactivation would include inhibitors for Pim-1 and -3 kinases, CDK6 kinase, or NPM.  
 
Another important focus for targeted therapies in the future against KSHV-induced 
malignancies will be introduction of reliable prognostic markers to assess which 
patients are likely to be at risk for a poor response to a given treatment, for instance 
due to increased viral reactivation in their tumors. In this regard, the data in this thesis 
imply that pNPM Thr199 levels could be further explored as a prognostic marker  
for a more aggressive disease or poor outcome for therapies in patients with  
KSHV-associated malignancies. 
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